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SUMMARY 
 
This study was done with the objective of identifying the pharmacokinetic profile 
of total and free mycophenolic acid (MPA), and mycophenolic acid glucuronide 
(MPAG) and pharmacodynamic profile of MPA in mycophenolate mofetil (MMF) 
in combination with sirolimus and steroids and also to establish the 
pharmacokinetic (PK) and pharmacodynamic (PD) relationship. Population PK-
PD models for both free and total MPA was also developed to quantify average 
population pharmacokinetic and pharmacodynamic parameters value and to 
evaluate the influence covariates on the PK-PD variability. 
 
In this study, two groups of patients were included. Altogether 6 stable renal 
transplant patients for the basic PK-PD profile study and 46 patients for the PK-
PD modeling from Singapore General Hospital (SGH) were included in the study 
of their follow-ups. 
 
The established reserved-phase high performance liquid chromatography (HPLC) 
methods with UV detection were used to quantify MPA and MPAG in patients’ 
plasma, urine and ultrafiltrates. Determination of the inosine monophosphate 
dehydrogenase (IMPDH) activity was performed using the established methods 
with some minor modification.  
 
A total of 36 plasma MPA concentration-time data obtained from 6 patients who 
had MMF for more than 3 months were analyzed and PK and PD parameters were 
shown and discussed. 
                viii
 Pharmacokinetic studies during dosing intervals of free and total MPA and MPAG 
from the same patients were also analyzed. It is observed that after oral 
administration of MMF, there is a rapid increase in total and free MPA 
concentration during absorption phase, followed by a distribution and elimination 
phase, reached the peak at about 0.5 h and descended gradually and inverse 
relationship was found for the PD. The PK parameters of MPAG were also 
shown. 
 
For the pharamacodynamic response of both free and total MPA in population, 
WinNonMix software (non linear mixed effects modeling) was used for analysis. 
Covariates such as age, sex, ethnic groups may affect PK and PD aspects. To 
determine these effects, PK and PD models were developed. Population PD 
parameters of structural basic and final model for PK-PD relationship of total and 
free MPA concentration and responses were also identified. In this study, PK-PD 
model for total drug concentration and response did not identify any significant 
covariates relationship. However, only one covariate, white blood cells count 
(WBC), had shown significant for the PK-PD model for free drug concentration 
and response. 
 
However, further investigations with a large number of patients are needed to 
fully explore the impact of covariates on the PK-PD relationship between MPA 
and IMPDH activity. 
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CHAPTER 1   
INTRODUCTION 
 
1.1 BACKGROUND OF ORGAN TRANSPLANTATION 
 
Organ transplantation means removing a whole or part of a healthy organ from one 
body (the donor) and putting it in another body (the recipient) to replace the 
recipient’s damaged or failing organ in order to prolong or save his or her life. In 
cases of skin grafts, and recently, face transplant, it is to enhance the quality of life. 
 
Transplantation can be categorized according to donor and recipient as follows: 
a) Autograft – Autograft means transplantation of tissue from one part of 
own body to another part, e.g. skin grafts, vein extraction in Coronary 
Artery Bypass Graft (CABG). Returning back the stem cells to the same 
body and string is own blood for later transfusion is also considered as 
autograft. There will be no problem with rejection because the body 
recognizes its own tissue. 
 
b) Allograft – Allograft means transplantation of an organ or tissue from 
genetically non-identical member of the same species. Most of the 
transplantations in human fall into this category. Tissue rejection is one 
of the major problems in this type of graft as recipient’s body fights 
back the transplant organ as a foreign body. 
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c) Isograft – It is transplantation of organ or tissue from the donor who is 
genetically identical with the recipient i.e. identical twins. Tissue 
responses in these operations are the same as autograft. 
 
d) Xenograft – Xenograft means transplantation of organ or tissue from 
donor of different species other than recipient. Replacement of damaged 
human heart valves with porcine heart valves is a common procedure of 
xenograft. But transplantation of the whole of baboon’s heart to human 
failed. Non-human xenografts are done for research [1]. 
 
1.2 BACKGROUND OF RENAL TRANSPLANT 
 
The organs that can be transplanted nowadays are heart, lungs, liver, kidney, 
pancreas, cornea, and intestines. Although heart transplant made the headlines, 
kidney transplantation is the most common transplant procedure.  In fact, kidney 
is the first organ to be transplanted successfully. As a person can live with only 
one kidney, the donor can be either living or deceased.  
 
Renal transplant is considered in those patients with end-stage renal disease who 
can tolerate transplant surgery. Table 1.1 shows the criteria of indications and 





Table 1.1 Summary of kidney transplantation 
Diseases that can 
cause renal failure 
which will 
eventually lead to 
renal dialysis and 
transplant 
Contraindications to 
kidney transplantation Criteria for donors 
Contraindications for 




Age – patients more than 
70 years of age 
Compatible ABO 
typing with potential 
recipient 
Person with single 




Patients having heart or 
circulatory disorders 
Age – between 18 
and 65 years old 
History of kidney stone 
or kidney disease 




Active infectious disease 
 
Psychosocially 






People from high risk 
occupation like military, 
special forces, 
professional football 
player or other contact 
sports 
 
 Active substance abusers Ability to give 
informed consent 
People having diseases 
like HIV AIDS, 
Hepatitis, Tuberculosis, 
cancer, diabetes etc. 
 Those with psychological 
or behavioral 
abnormalities since they 
cannot follow post 




biologically related to 
the recipient or if not, 





 Morbidly obese patients All unrelated donors 
must have a 
psychiatric evaluation 
Pregnancy 
   Active substance abuser 
   History of psychological 
instability 
   donor with risk to 
anesthesia 
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1.3 OVERVIEW OF COMBINATION DRUG THERAPY IN 
TRANSPLANTATION 
 
The success of organ transplants depends on controlling the rejection of transplanted 
organ by the recipient. These transplant rejections, both acute and chronic, are in fact 
the normal function of the body immune system, which is to defend the body against 
foreign invasion [2].  
 
The discovery of calcineurin inhibitors about 20 years ago was a turning point in 
organ transplantation [3]. Cyclosporine, a calcineurin inhibitor, is a primary 
immunosuppressive drug used in renal transplant to prevent acute transplant rejection. 
Cyclosporine acts by inhibiting cytokines such as interleukin–2 production and leads 
to a decrease in formation of activated lymphocytes [2]. But the drawback of 
cyclosporine is its side effects such as nephropathy, delayed graft failure (DGF), 
hypertension and gingival hyperplasia, among which the most important ones are 
nephrotoxicity and DGF, especially in renal transplant patients [3]. 
 
New immunosuppressants are now discovered and they are used in various 
combinations with cyclosporine and steroids. The application of newer drugs can 
avoid a prolonged use of cyclosporine to offset its renal toxicity and DGF effect. 
Combination therapies decrease the rejection rate and improve the outcome of the 
transplant. Patient’s allograft survival rates become higher by lowering circulating 
plasma concentrations while maintaining efficacy and minimizing toxicity and fewer 
side effects and can be tailored to individual patient’s reaction to drugs and financial 
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status. Moreover, these combination drug regimens have allowed the physician to use 
lower-dose therapy [4]. 
 
The anti-rejection drugs that are commonly used in kidney transplants are 
mycophenolate mofetil (MMF), sirolimus (SRL) and tacrolimus (TAC). 
Mycophenolate mofetil, an immunosuppressive drug used since 1995 [5], is a 
precursor of mycophenolic acid (MPA). MMF is quickly absorbed after oral 
administration and hydrolyzed to MPA, an active moiety in the body. MPA prevents 
proliferation of both T and B lymphocytes by inhibiting the de novo pathway of 
guanosine nucleotide synthesis [5]. MMF is used in renal allograft to prevent acute 
rejection. 
 
Tacrolimus (TAC), a macrolide produced by the fungus Streptomyces tsukubaensis, 
binds to intercytoplasmic immunophilin (FKBP 12) in the body and forms an active 
complex, which acts as a calcineurin inhibitor and is used in combination with other 
immunosuppressant for the prophylaxis of liver and kidney transplant rejection [6]. 
Like another calcineurin inhibitor cyclosporine, TAC is also mainstay of prevention 
of acute allograft rejection. But the effect of tacrolimus is far more superior to that of 
cyclosporine in its anti-rejection action. It also has a superior cardiovascular profile 
[3]. 
 
Sirolimus (SRL) is another macrolide produced by Streptomyces hygroscopicus. 
Sirolimus binds to the same FK binding protein (FKBP 12) which also binds with 
tacrolimus, but the complex formed has a different action than tacrolimus. It does not 
have anti-calcineurin activity. Sirolimus complex acts by inhibition of the activation 
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of the mammalian target of rapamycin (mTOR), which is a key regulatory kinase. 
This inhibits cytokine-mediated T cell proliferation [7]. Sirolimus acts at the later 
stage of cell cycle than calcineurin inhibitors by inhibiting the post interleukin-2 
receptor mTOR. The dose-normalized trough level of sirolimus is different when co-
treated with MMF or cyclosporine. 
 
Various regimens of drug combination are being on trial for different organ 
transplants. The advantages of combination therapy are less side effect and toxicity 
and because of synergistic effect of some drugs, lower dosage can be used. The 
outcome of suppressing acute and chronic allograft rejection becomes better.  If one 
anti-rejection drug is having toxicity or side effect, it can be withdrawn and replaced 
by another antisuppressive agent. But the draw back of co-treatment is patient’s 
exposure to particular drug which may be altered since one drug may influence the 
serum level of another by various means. There is inter- and intra-patient variability in 
pharmacokinetics of immunosuppressant as well. It has been observed in some trials 
that MPA plasma concentration expression is higher when co-treated with sirolimus 
and tacrolimus than when co-treated with cyclosporine [8]. The dosage of any drug 
should be monitored by monitoring the plasma levels of the drugs in concomitant 












MMF is the pro-drug, 2-morpholinoethyl ester of mycophenolic acid (MPA), which is 
the active moiety in the body [9]. The chemical name for MMF is 2-morphoethyl (E)-
6-(1, 3-dihydro-4-hydroxy-6-methoxy-7- methyl-3-oxo-5-isobezofuranyl)-4-methyl-
hexenoate. The chemical formula is C23 H31 NO7 and the molecular weight is 433.50. 
MMF shows free solubility in alcohol, but is only slightly soluble in water [10]. 
 













Figure 1.1 Chemical structure of mycophenolate mofetil (MMF) 
 
MMF is easily absorbed and hydrolyzed to mycophenolic acid (MPA) in the body. 
The chemical name for MPA is 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-
oxo-5-isobenzofuranyl)-4-methyl-4-hexenoic acid. The chemical formula is C17H20O6 
and has a molecular weight of 320.34. It is a weak dibasic acid (acidic drug) [11].  










Figure 1.2 Chemical structure of mycophenolic acid (MPA) 
 
MPA is then metabolized in the body to a major metabolite mycophenolic acid 
glucuronide (MPAG), whose chemical structure is as follows [5].  The chemical 



















Figure 1.3 Chemical structure of mycophenolic acid glucuronide (MPAG) 
 










1.4.2.1 History of MMF 
 
Mycophenolate mofetil is a new drug used in prophylaxis of acute rejection in organ 
transplantations. MPA was first found in 1896 from Penicillium fungus. Antifungal 
and antibacterial effects of MPA were noted in the 1940s, but its immunosuppressive 
action was discovered in the late 1960. Antitumor activity was described in 1968 and 
MPA was further studied for psoriasis but did not gain clinical use [10].  
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The use of MMF was introduced in organ transplant in early 1990 but only in 1995 its 
use was approved by the US Food and Drug Administration (FDA). MMF was first 
administered in renal transplant in May 1995, cardiac transplant in February 1998 and 
hepatic allograft in July 2000 [5]. It is marketed by Roche Pharmaceuticals as 
CellCept®. 
 
MMF is produced from the fungus Penicillium stoloniferum. Acute rejection occurs in 
about half of the renal transplants. Since acute rejections are thought to reduce later 
survival of the grafts and the patients, various drug regimens are on trial for the best 
possible combination with minimum side effects. After the event of MMF, although it 
is more expensive than azathioprine, MMF is being used more than azathioprine 
because the former has less bone marrow depression and associated with less 
incidence of acute rejection [5].  
 
MMF also prevents the use of high doses of corticosteroids for rescue therapy of acute 
rejection. MMF is given with cyclosporine, tacrolimus, sirolimus and corticosteroids 
in various combinations. One of the side effects of cyclosporine is renal toxicity. 
Cyclosporine dose can be reduced or even totally tailed off when use in conjunction 
with MMF. This is especially beneficial in renal transplant patients. 
 
1.4.2.2 Indications and clinical uses 
 
Immunosuppression therapy in clinical transplantation has evolved since the routine 
use of the triple drug regimen of a calcineurin inhibitor cyclosporine A (CsA), 
prednisolone and azathioprine. A calcineurin inhibitor tacrolimus (TAC), a mTOR 
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(mammalian target of rapamycin) inhibitor Sirolimus (SRL) and an IMPDH inhibitor 
mycophenolate mofetil (MMF) are recently introduced immunosuppressants, which 
effectively prevent allograft rejection with a low incidence of adverse effects in the 
impaired natural host defenses. Immunosuppressive drugs are regularly used in 
combinations, intended to maximize immunosuppression while reducing the side 
effects of each individual drug.  
 
Currently manufacturer guidelines for mycophenolate mofetil dosage are standard for 
all individuals within a transplant group which are largely based on results from three 
randomized, double-blind, multicenter phase III trials. In adult renal transplant 
recipients, an oral dose of mycophenolate mofetil 1g twice daily is recommended 
[12]. Based on the clinical trials carried out in the Western Population, the 
recommended dosage of MMF for prophylaxis of organ rejection in renal transplant 
patients is 2 to 3 g per day, given 2 to 3 divided dose [12]. 
 
Other non-FDA-approved therapeutic uses of MMF have also been reported in 










Table 1.2 Other non-FDA-approved therapeutics uses of MMF reported in 
literatures 
Disease Uses References 
 Prophylaxis of graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation [13] 
Prophylaxis of autoimmune hemolytic anemia [14] 
Prophylaxis of auto immune thrombocytopenia 
purpura [15] 
Prophylaxis of pemphigus [16] 
Prophylaxis of systemic lupus erythematosus 
(SLE) [17] 
Prophylaxis of autoimmune nephritis [18] 
Prophylaxis of autoimmune rheumatic disease [19] 
autoimmune diseases 
Prophylaxis of autoimmune hepatitis [20] 
Prophylaxis of sarcoidosis [21] 
inflammatory diseases 
Prophylaxis of Crohn’s disease [22, 23] 
 
 
1.4.2.3 Pharmacodynamic properties 
 
Pharmacologically active moiety of MMF is MPA, which is a potent, selective, 
noncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase 
(IMPDH) [24]. The selective action of MPA is on proliferating lymphocytes due to 





 Figure 1.5 Mechanism of action of MPA on IMPDH enzyme 
 
The mechanism of IMPDH-catalyzed formation of xanthine monophosphate (XMP) 
from inosine monophosphate (IMP) follows bi-bi ordered kinetics. IMP binds to the 
enzyme first, followed by binding of NAD to a second site. Catalysis of IMP to form 




MPA inhibition is uncompetitive with respect to both IMP and NAD and data are 
consistent with binding of MPA to IMPDH after formation of the ternary complex of 
IMPDH, NAD and IMP [25]. Both T and B lymphocytes are more dependent on this 
pathway than other cells types because, unlike other cells, lymphocytes cannot utilize 
salvage pathways for purine synthesis. 
 
There are three other mechanisms that may also contribute to the efficacy of 
mechanism of action in preventing allograft rejection and other applications. First, 
MPA can induce apoptosis of activated T-lymphocytes, which may eliminate clones 
of cells responding to antigenic stimulation. Second, by depleting guanosine 
nucleotides, MPA suppresses glycosylation and the expression of some adhesion 
molecules, thereby decreasing the recruitment of lymphocytes and monocytes into site 
of inflammation and graft rejection. Third, by depleting guanosine nucleotides, MPA 
also depletes tetrahydeobiopterin, a co-factor for the inducible form of nitric oxide 
synthase (iNOS). MPA therefore suppresses the production by iNOS of NO, and 
consequent tissue damage mediated by peroxynitrile [26]. 
 
MPA is a fivefold more potent inhibitor of the type II isoform of IMPDH, which 
expressed in activated lymphocytes, than of the type I isoform of IMPDH, which is 
expressed in most cells types. Therefore, MPA has a more potent cytostatic effect on 
lymphocytes than on other cells types. This is the principal mechanism by which 
MPA exerts immunosuppressive effects [26]. 
 
Addition of guanosine or deoxyguanosine can reverse the cytostatic effect of MPA on 
lymphocytes [27].  MPA is said to be selective on lymphocytes because azathioprine   
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inhibits enzymes other than IMPDH, so azathioprine can be toxic to other cells that 
can use alternative salvage pathways for purine synthesis. Proliferation of both T and 
B lymphocytes due to mitogenic or allospecific stimulations are inhibited by MPA. 
 
MPA also reduces the glycosylation of lymphocytes and monocyte glycoproteins by 
depleting intercellular guanosine triphosphate, thereby reducing the recruitment of 
leukocytes to site of inflammation and allograft rejection. 
 
Mycophenolic acid does not block the production of interleukin-1 (IL-1) and 
interleukin-2 (IL-2), which are the sites of action of tacrolimus and cyclosporine. 
Therefore, MPA has no competition with those two anti-rejection drugs nor with 
sirolimus, which is mTOR inhibitor. 
 
Aside from the lymphocytes, MPA also inhibits proliferation of vascular smooth 
muscles, mesangial cells and proliferating monocytes. 
 
Apart from MMF, the other new inhibitors of de novo nucleotides synthesis include 
mizoribine (MZ), brequinar (BQR) and leflunomide (LEF). MMF and MZ inhibits the 
IMPDH and create a selective immunodeficiency in T and B lymphocytes. However, 
MMF has been approved in a number of countries and MZ has been approved in 



















Sample Co-therapy  Ref: 
8 Ribaviring British* (London) 85 (4-183) Erythrocytes  [29] 
  Australian* (Australia) 178±29 Incubated in HSA  [30] 
 1 g German* (Germany) 0.34
c            Whole Blood Cells (0h) CsA/Steroids [31] 
2    0.125c In Whole Blood Cells (2h)   
   0.025c MNC (0,2h)   
26 (Patients) 1 g German* (Germany) 108.6±13.3
d   [32] 
27 (healthy)   22.5±1.7d    
60 (healthy) 1 g  Caucasian (Germany) 
18.39±6.24  
( 4.72-32.92)  MNC  [33] 
   15.4±3.44e        
     4.1±2.4 (after)    
10 (Patients)   8.4-21.2    
50/15 1 g Caucasian  (Germany) 
17.7±6.4  
(3.9-32.9) MNC CsA/Steroids [34] 
1male 1 g (oral) Caucasian (Germany) 6.25 MNC CsA/Steroids [35] 
 IV  7.61    
 oral   10.2e    
 IV  16.7e    
6 1 g Caucasian (Germany) 
9.4±3.3  
(5.6-15.2) MNC CsA/Steroids [36] 
48  Caucasian (Germany) 9.35±4.22 Pretransplant  [37] 









1g MMF  Norwegian* (Norway) 
0.78f   







(0.08-0.28)b,g    
Abbreviation: MMF=mycophenolate mofetil; CsA=Cyclosporine; MNC=peripheral blood mononuclear cells; 
IMPDH=inosine monophosphate dehydrogenase activity 
a pmol/106MNC/h      
b μmol/L cell lysate/min      
c nmol/min/cell lysate      
d pmol/h/mg protein      
e base line activity      
f median       
g not on MMF       








1.4.2.4 Pharmacokinetic properties 
 
Absorption: MPA is given orally or intravenously as precursor MMF to increase 
bioavailability. After oral administration, MPA is rapidly and completely absorbed 
from the GI tract and extensively hydrolyzed into the active form of MPA by esterase 
in liver [12, 40]. Because of rapid absorption, Cmax of MPA is reached within 1 to 2 
hours of oral administration [41].  
 
The mean absolute bioavailability of oral MMF relative to intravenous MMF (based 
on MPA AUC) was 94%. The area under the plasma-concentration time curve (AUC) 
for MPA appears to increase proportionality with dose. Although food had no effect 
on the extent of absorption (MPA AUC) of MMF, MPA Cmax was decreased by 40% 
in the presence of food [42]. 
 
Distribution: The mean±SD apparent volume of distribution (Vd) is approximately 
3.6±1.5 L/kg after IV administration and 4.0±1.2 L/kg after oral administration in 
healthy volunteers. MPA is expensively bound to human serum albumin which is 
97%.However, at clinically relevant concentrations, MPA is almost completely 
(>99%) bound to plasma albumin and free fraction is ranging from 0.71% - 2.12% 
[10].  
 
The primary metabolite MPAG is 82% bound to human serum albumin in stable renal 
transplant patients. However, at higher MPAG concentration (in patients with renal 
impairment or delayed renal graft function), the binding of MPA may be decreased as 
a result of competition between MPA and MPAG for protein binding [42]. 
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Metabolism: Following oral absorption, MMF is rapidly hydrolyzed to MPA, the 
active immunosuppressive entity, by esterases in the gut wall, liver and possibly lung 
and peripheral tissues. Subsequently, MPA is then extensively metabolized into 
mycophenolate 7-O-glucuronide (7-O MPAG) by uridine diphosphate glucuronyl 
transferase in liver, gastrointestinal tract and kidney. 
 
 MPAG is usually present in the plasma at 20 to 100 fold higher concentrations than 
MPA but it is not pharmacologically active. Two other minor metabolites are formed, 
of which only acyl-glucuronide (AcMPAG) has MPA like activity and M-3 is an 
inactive metabolite, which is present only in trace amount in human plasma [43].  
 
MPAG is excreted in urine and bile. But MPAG excreted in bile is hydrolyzed to 
MPA and reabsorbed. This reversal of MPAG to MPA via enterohepatic circulation is 
responsible for the second peak in plasma MPA level 6 to 12 hours after oral dosing 
[12]. Only 10-20% of the drug is being in the active form during enterohepatic 
circulation but the elimination half-life of the active compound is extended [44]. 
 
Excretion: Only a small amount of drug that can be negligible is excreted as MPA 
(<1% of dose) in the urine. Approximately 87% of administered dose is secreted in 
urine via active tubular secretion as MPAG and small amount of MPAG (6%) is 
excreted in feces. MPAG is the primary urinary excretion product of the drug [10]. 
Neither MPA nor MPAG is eliminated by haemodialysis. The mean elimination half 
life of MPA is 9 to17 hours. 
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All the pharmacokinetic data for both MPA and its major metabolite MPAG are 

























Table 1.4 Pharmacokinetic parameters of mycophenolic acid in different transplant groups of multiple 










Co-therapy Tmax (h) C0 (mg/L) Cmax (mg/L) 
AUC0-12 
(mg.h/L) Ref: 
1 1 g Caucasian (Germany) CsA/Steroids 1 2.1 21.7 65.6 [35] 
 0.5 g (IV)   1 0.7 28.5 56.2  
10 1 g (1wk) White (Germany) CsA/Steroids 1.9±0.7 0.7±0.1 7.0±1.3 22.1±1.8 [45] 
 1 g (3wk)  CsA/Steroids 1.5±0.2 1.2±0.4 10.2±1.9 30.9±4.6  
 500 mg (6wk)  CsA/Steroids 0.8±0.5 2.6±1.9 15.2±7.4 52.0±26.1  
 500 mg (3mo)  CsA/Steroids 1.0±0.6 2.8±1.4 14.4±6.8 36.7±21.2  
 500 mg (12mo)  CsA/Steroids 1.8±0.5 3.6±3.2 17.4±10.2 43.8±25.5  
24 1 g Chinese (China) CsA/Steroids  1.7±0.8 17.1±7.2 49.3±11.1 [46] 




CsA/Steroids 2.1±1.5 1.2±0.8 16.2±11.8 45±11.8 [47] 
10 1 g Spanish* (Spain) CsA/Steroids 1.4±1 2.1±1.2 12±5.7 49.8±24.8 [48] 









 1 g (6wk)  TAC/Steroids  2.2 (0.2-71)a  
59.9 
(18.6-211)a  
 1 g (3 mo)  TAC/Steroids  2.4 (0.3-5.7)a  60 (24-111)
a  





10 1 g (2d) Australian* (Australia) CsA/Steroids 2.2±0.5  11.1±1.3 42.3±2.3 [50] 
 1 g (5d)  CsA/Steroids 1.9±0.4  11.9±2.5 35.7±3.2  
 1 g (28d)  CsA/Steroids 1.6±0.4  14.9±1.9 37.5±2.7  
7 750 mg  CsA/Steroids 1.6±1.2 1.4±0.6 14.1±11.7 41.7±13.2  
10 500 mg  CsA/Steroids 0.9±0.6 1.8±0.7 16.2±12.5 42.9±17.9  






(1.5-8)a 1.7 33.4 74.7   
 African American       
  Asian (USA)       
19 1 g French* (France) CsA/Steroids 1.6
c 1.5c 11.7c 44.9b [52] 
12 1 g  SRL/Steroids 0.9c 3.8c 12.8c 30.5b  
10 1 g Caucasian  (Italy) CsA/Steroids  0.69±0.31 15.44±4.07 25.46±6.84 [2] 
11 1 g  SRL/Steroids  2.39±1.17 15.07±11.22 36.68±15.74  
10 500 mg  CsA/Steroids  0.42±0.28 7.89±3.02 12.01±4.92  
11 500 mg  SRL/Steroids  1.47±1.16 7.85±3.16 20.64±6.58  
12 1 g Caucasian (France) CsA/Steroids  2.76±1.57  51.7±16.7 [53] 
15 500 mg  SRL/Steroids  2.32±1.72  32.3±12.6  
 750 mg  SRL/Steroids  3±1.87  54.1±17.6  
 1 g  SRL/Steroids  4.7±2.44  70.9±19.3  
Abbreviation: MMF=Mycophenolate mofetil; CsA=Cyclosporine; TAC=Tacrolimus; SRL=Sirolimus; IV=intravenous; 
C0=trough plasma concentration; Cmax=maximum plasma concentration; Tmax=time to reach Cmax; AUC0-12=area under the 
plasma concentration-time curve from 0 to 12 h; EP-MCS=enteric-coated mycophenolate sodium;  b.d.=twice daily; d=day; 
wk=week; mo=month 
All the values are expressed as mean±SD unless specified otherwise. 
a median (range). 
b AUC0-9
c dose normalized 
 *Ethnic group not reported 
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Table 1.5 Pharmacokinetic parameters of MPAG in different transplant groups of multiple dosing 











Co-therapy Tmax (h) 
C0 
(mg/L) Cmax (mg/L) 
AUC0-12 
(mg.h/L) Ref: 
10 1g (1wk) 
White 
(Germany) CsA/Steroids 3.9±1.2 163±25 215±26 2095±259 [45] 
 1g (3wk)  CsA/Steroids 3.3±0.8 137±21 193±22 1901±212  


























10 1 g (2d) Australian* (Australia) CsA/Steroids    1983±209 [50] 
 1 g (5d)  CsA/Steroids    1732±272  
 1 g (28d)  CsA/Steroids    1572±127  








(0.25-8.0)a 84 223.7 1724  
  Mixed race       
  Asian (USA)       
19 1 g French* (France) CsA/Steroids 3.0
c 101.7c 164.5c 1200.4b,c [52] 
12   SRL/Steroids 2.1c 88.2c 137.5c 980.0b,c  
Abbreviation: MMF=mycophenolate mofetil; CsA=Cyclosporine; TAC=Tacrolimus; SRL=Sirolimus; C0=trough plasma 
concentration; Cmax=maximum plasma concentration; Tmax=time to reach Cmax; AUC0-12=area under the plasma 
concentration-time curve from 0 to 12 h; EP-MCS=enteric-coated mycophenolate sodium;  b.d.=twice daily; d=day; 
wk=week; mo=month 
All the values are expressed as mean±SD unless specified otherwise. 
a median (range). 
b AUC0-9
c dose normalized 






Structurally resembling tacrolimus (TAC), sirolimus (SRL) contains the same 
tricarbonyl region including an amide, a ketone and a hemiketal, but a triene segment 
in SRL differentiates these two drugs. Because of this structural difference, SRL is a 
hydrophobic drug that has low stability in aqueous solution [10]. 
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 Figure 1.6 Chemical structure of sirolimus (SRL) [Rapamycin] 
 
 
1.5.1.1 History of sirolimus 
 
Sirolimus (rapamycin) known as Rapamune® (RAPA), is a macrolytic triene 
antibiotic produced by Streptomyces hygroscopicus, a streptomycete that was isolated 
from a soil sample collected from Easter Island (Rapa Nui) [54]. It was discovered 
initially as an antifungal agent in the mid-1970s. Because of its immunosuppressive 
effects, it was not further developed for clinical use as an antibiotics [10].  
 
SRL is an mTOR (mammalian target of rapamycin) inhibitor, which inhibits cell 
proliferation driven by growth factors [55].  Sirolimus was initially approved for renal 
transplantation by the Food and Drug Administration in 1999 [56]. It is a second 
generation potent immunosuppressive agent with narrow therapeutics, which provides 






1.5.1.2 Pharmacodynamic properties 
 
Because it is lipophilic, SRL passes through cell membranes easily, and the segment 
of macrolactam ring identical to tacrolimus binds to cytosolic FK506-binding proteins 
(FKBP). The consequent mechanisms of action for tacrolimus-FKBP and SRL-FKBP 
complexes differ in several ways. Unlike tacrolimus, SRL does not inhibit calcineurin 
phosphatase. Inside the T cells, rapamycin-FKBP-12 complex binds to mammalian 
target of rapamycin (mTOR), inhibiting its activation as shown in Figure 1.7. This 
suppresses T lymphocyte proliferation in the transition from G0 to G1 phase of the cell 
cycle [58].  
 
The mechanism of action of SRL is distinct from that of the calcineurin inhibitors 
(CI), such as cyclosporine and tacrolimus, whose function is primarily dependent on 
the inhibition of cytokine gene expression. SRL acts by binding the TOR protein 
kinases, which in turn prevents cell cycle progression by blocking the ability of T 
cells to proliferate in response to interleukin (IL)-2 stimulus. 
 
1.5.1.3 Pharmacokinetic properties 
 
 SRL is rapidly but poorly absorbed following oral administration. The approximate 
oral bioavailability of SRL is 15% in renal transplant recipients due to extensive 
intestinal and hepatic metabolism, with a time to peak absorption ranging from 0.7 to 
3 hours after dosing and the mean elimination half life is about 60h and plasma 
clearance is about 210 ml/h. Its absorption is affected by high fat meals [10, 57, 58]. 
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After absorption, SRL is rapidly distributed to the red blood cells and approximately 
more than 95% of the drug is bound to red blood cells, with its high lipophilicity 
simplifying this process. The binding to red blood cells may also account for the 
increased potency that SRL displays in comparison to cyclosporine. 
 
Blood/plasma ratio is about 36 and plasma volume of distribution (Vd) is about 1.7 
L/Kg [58]. SRL is extensively metabolized by the hepatic CYP3A4 isozyme and is 
also a substrate in the p-glycoprotein pump of the intestinal wall. The plasma 
clearance of SRL is affected by both of these pathways and displays a large inter-
patient variability. More than 10 metabolites have been identified and some of them 
are low immunosuppressive activity in vitro. Their total plasma concentrations are 
less than that of the parent drug, and they do not contribute significantly to 
immunosuppression [58]. The majority of seven metabolites are formed via O-
demethylation and hydroxylation. The metabolites account for less than 10% of the 
immunosuppressant activity of SRL. These metabolites are excreted in bile and faces 
[10].  
 
The therapeutic window of SRL may be relatively narrow. Hence, the optimal use of 
SRL requires a careful attention to the maintenance of therapeutic levels. Sirolimus is 
not increased by co-medications of acyclovir, glyburide, digoxin, nifedipine, 
norgestrol/ethinyl estradiol, prednisolone, trimethaprim and sulfamethoxazole. 
However, diltiazem, ketoconazole and cyclosporine increase sirolimus plasma 
concentration, while rifampin decreases sirolimus exposure. Toxicities include 
thrombocytopenia and hyperlipidemia. A tentatively suggested therapeutic range is 8-
15 μg/L of whole blood immediately post-transplant [58]. 
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1.6 COMBINATION OF MYCOPHENOLATE MOFETIL WITH SIROLIMUS 
AND DRUG-DRUG INTERACTION 
 
Figure 1.7 Mechanism of action of MMF and SRL 
 
 
MMF and SRL are potent non-nephrotoxic xenobiotic immunosuppressants [55]. 
Several studies have reported a lower exposure to MPA in patients receiving MMF in 
combination with cyclosporine than in those receiving MMF and tacrolimus or MMF 
alone. The patients taking MMF and SRL experience a higher exposure to MPA and a 
lower exposure to MPAG than those being treated with MMF and cyclosporine. The 
same dose of MMF would lead on average to a 50% increase in the AUC of MPA in 
patients receiving sirolimus compared to cyclosporine trough plasma concentration 




OBJECTIVES OF THE STUDY  
 
Mycophenolate mofetil is widely used in combination with either cyclosporine or 
tacrolimus or sirolimus and corticosteroids for rejection prophylaxis in renal and heart 
transplant patients. However, there are currently limited data on the PK and PD 
profiles of MPA in Asian population, and the optimal dose for MMF in Asian patients 
has yet to be established. Hence, this study aims to address these issues as to 
determine the PK profiles of MPA and MPAG in the local renal transplant patients 
and to determine the PK-PD correlations.  
 
Moreover, since plasma concentration measurement is only a surrogate for 
pharmacological effect, PD monitoring in terms of determining the IMPDH activity in 
lymphocytes would be useful in the direct investigation of biologic response to MMF 
therapy. Investigations at PD level would aid the in-depth study of clinical outcome in 
terms of efficacy and tolerability, especially since there are only limited data in this 
area. Hence, the primary objective of the study is to identify the pharmacokinetic 
profiles of total and free MPA and MPAG and pharmacodynamic profiles of MPA 
and to establish the PK-PD relationship for the adult stable renal transplant patients 
 
Finally, attempt would be made to develop a population pharmacokinetic 
pharmacodynamic model for total and free MPA in stable adult renal transplant 
patients, to quantify average population pharmacokinetic and pharmacodynamic 






3.1 HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD FOR 
THE DETERMINATION OF TOTAL MPA AND ITS METABOLITE MPAG 
IN BIOLOGICAL SAMPLES 
 
Mycophenolic acid (MPA) has gained wide-spread acceptance as the antimetabolite 
immunosuppressant of choice in solid organ transplant regimens and many 
researchers have reported methods to determine MPA and its metabolites. In the 
present study, an established method [5] using reversed-phase high-performance 
liquid chromatography (HPLC) with ultraviolet (UV) detection was employed to 
measure total MPA concentration and its metabolite MPAG in biological samples like 
plasma and urine. This method was successfully applied to the routine analysis of 
total MPA and MPAG in the biological samples to study the pharmacokinetics of total 
MPA and MPAG in stable renal transplant patients. 
 
3.1.1 Materials and methods 
 
3.1.1.1 Chemicals and reagents 
 
MPA was obtained from Fluka Chemie (Buchs, Switzerland). MPAG was a generous 
gift from Roche Bioscience (Palo Alto, CA, USA). Potassium hydroxide was 
purchased from Merck (Darmstadt, Germany) and potassium dihydrogen phosphate 
was from Nacalai Tesque (Kyoto, Japan). The ion-pairing reagent, 
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tetrabutylammonium hydrogen sulphate (TBAHS), was obtained from Fluka Chemie 
(Buchs, Switzerland). HPLC grade acetonitrile was purchased from Fisher Chemicals 
(New Jersey, USA). Milli-Q (18 MΩ) water, used throughout the study, was 
generated by a Millipore™ Continental Water Systems (Burlington, MA, USA). 
Pooled blank human plasma was obtained from the blood bank of the National 
University Hospital (NUH), Singapore. Blank human urine was from a single healthy 




Chromatographic analyses were performed using a Shimadzu integrated HPLC 
system LC-2010A liquid chromatography (Shimadzu Corporation, Kyoto, Japan) 
equipped with a UV detector, autosampler, column oven and data processing software 
(Shimadzu Class VP software version 6.10). All chromatographic separations in this 
study were performed using an XTerra™ RP18 analytical column (150 mm × 4.6 mm 
i.d., particle size 5 μm) (Waters Corporation, Milford, MA, USA), connected with an 
XTerra™ RP18 guard column (20 mm × 3.9 mm i.d., particle size 5 μm) (Waters) and 
a 0.5 μm stainless steel frit pre-column filter (Upchurch Scientific, Oak Harbor, WA, 
USA).  
 
3.1.1.3 Chromatographic conditions 
 
The running buffer solution used for this reversed-phase iron-pair HPLC assay 
composed of 40 mM TBAHS in 20 mM potassium dihydrogen phosphate that was 
prepared and adjusted to pH 5.5 (EcoMet pH meter, Istek, Seoul, Korea) with 2 M 
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potassium hydroxide. This solution was then filtered through a 0.2 μm hydrophilic 
polypropylene membrane filters (Pall Corporation, Michigan, USA) and degassed 
using ultrasonic bath (Transsonic T460, Singen, Germany) before use. The mobile 
phase for this assay of MPA and MPAG consisted of the above running buffer 
solution – acetonitrile (73:27, v/v), mixed on-line and delivered isocratically at a flow 
rate of 1.0 ml/min. The temperature of the column oven was maintained at 24° C. 
Each sample was injected onto the column at a constant volume of 20 μl for an 
analysis run of 15 min. The UV detection wavelength was set at 304 nm and 215 nm 
for the chromatographic analyses of plasma and urine samples respectively. Sample 
preparation in details will be mentioned later in next chapter (Chapter 4). 
 
3.2 HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD FOR 
THE DETERMINATION OF FREE MPA AND ITS METABOLITE MPAG IN 
ULTRAFILTRATES 
 
In this study, an established method [59] using reversed-phase high-performance 
liquid chromatography (HPLC) with ultraviolet (UV) detection was also used to 
measure free MPA concentration and its metabolite MPAG in ultrafiltrates except for 
the ultrafiltration devices with different membrane molecular weight cutoff (MWCO). 
In this study, MWCO 2000 Da was used instead. This method was also successfully 
applied to the routine analysis of free MPA and MPAG in ultrafiltrates to study the 





3.2.1 Materials and methods 
 
3.2.1.1 Chemicals and reagents 
 
MPA was obtained from Fluka Chemie (Buchs, Switzerland). MPAG and the 
carboxybutoxy ether of MPA (MPAC) were generous gifts from Roche Bioscience 
(Palo Alto, CA, USA). Analytical reagent grade phosphoric acid 85% was purchased 
from Mallinckrodt Baker (Paris, KY, USA).HPLC-grade acetonitrile was purchased 
from Fisher Chemicals (New Jersey, USA). Pooled blank human plasma was obtained 
from the blood bank of the National University Hospital, Singapore. Milli-Q water 





Vivaspin -2- ultrafiltration devices (Vivascience Inc., Hannover, Germany), each 
consisting of a membrane with 2000 Da molecular weight cutoff (MWCO), were used 
in this study to improve protein removal. 500 μL of thawed plasma from each sample 
was incubated in a shaking water bath at 37 °C for 1 h and these plasma samples were 
added to each ultrafiltration device and centrifuged at 3000 g for 20 min at 37 °C 
using Avanti™ J-25 Centrifuge (Beckman Instruments, CA, USA) to obtain 
ultrafiltrates. This allowed for the direct injection of protein-free ultrafiltrates into the 






A Shimadzu integrated HPLC system LC-2010A liquid chromatograph (Shimadzu 
Corporation, Kyoto, Japan) equipped with a UV detector, autosampler, column oven 
and data processing software (Shimadzu Class-VP software version 6.10) was used. 
All chromatographic separations were performed using an Atlantis™ dC18 analytical 
column (150mm × 4.6 mm i.d., particle size 5μm) (Waters Corporation, Milford, MA, 
USA), connected with an Atlantis™ dC18 guard column (20 mm × 4.6 mm i.d., 
particle size 5 μm) (Waters Corporation, Milford, MA, USA). 
 
3.2.1.4 Chromatographic conditions 
 
The mobile phase consisted of 0.05% (v/v) aqueous phosphoric acid – acetonitrile 
(60:40, v/v), mixed on-line and delivered at a flow rate of 1ml/min. The column oven 
temperature was maintained at 30 °C. Each sample was injected at 100 μL for an 
analysis run of 15 min and UV detection was set at 304 nm. 
 
3.3 HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD FOR 
THE DETERMINATION OF IMPDH ENZYME ACTIVITY IN VITRO 
 
The first IMPDH assays measured the incorporation of radioactivity into purine 
nucleotides following the addition of [14C] hypoxanthine to cell suspensions and 
extracts. Other methods based on [14C] - and [3H]-labeling were used, but lately, 
methods without radioisotopes have been introduced. These are based on incubation 
of cell lysate supplemented with inosine 5’-monophosphate (IMP) and nicotinamide 
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adenine dinucleotide (NAD) and subsequent liquid chromatographic analysis of 
xanthine monophosphate (XMP) or xanthine, the end product of an enzymatic 
reaction, in order to express the IMPDH activity [39]. 
 
3.3.1 Materials and methods 
 
Method for the determination of IMPDH activity was adopted and modified from 
Glander et al. (2001) and Brouwer et al. (2006) by using isocratic ion-pair reversed 
phase HPLC [33, 38]. 
 
3.3.1.1 Chemicals and reagents 
 
Inosine Monophosphate Dehydrogenase Type II (IMPDH II), Xanthosine 5’ 
monophosphate (XMP), Inosine 5’ monophosphate (IMP) and Nicotinamide adenine 
dinucleotide (NAD) were purchased from Sigma (St. Louis, MO, USA). Sodium 
dihydrogen phosphate was from Merck (Darmstadt, Germany). The ion-pairing 
reagent, tetrabutylammonium hydrogen sulphate (TBAHS) and potassium chloride 
were obtained from Fluka Chemie (Buchs, Switzerland). Phosphate buffer saline ultra 
pure grade (10×PBS) was purchased from First Base Pte Ltd (Singapore). Trypan 
Blue Stain was from MP Biomedicals, LLC (Ohio, USA) and Protein Assay Kit was 
purchased from BIO-RAD Laboratories, Inc. (CA, USA). Methanol and acetonitrile, 
both were of high performance liquid chromatography (HPLC) grade, were purchased 
from Tedia Company Inc. (OH, USA) and Fisher Chemicals (New Jersey, USA), 
respectively. Milli-Q water (18MΩ), used throughout the study, was generated by a 




Chromatographic analyses were performed using a Shimadzu integrated HPLC 
system LC-2010A liquid chromatograph (Shimadzu Corporation, Kyoto, Japan) 
equipped with a UV detector, autosampler, column oven and data processing software 
(Shimadzu Class VP software version 6.10). All chromatographic separations in this 
study were performed using a ZORBAX™ Extend C18 analytical column (250 mm × 
4.6 mm i.d., particle size 5 μm) (Agilent Technologies, Santa Clara, CA, USA), 
connected with a guard column. 
 
3.3.1.3 Chromatographic conditions 
 
The buffer (pH 3.3) was prepared using 50 mM NaH2PO4 with 7 mM tetra-n-butyl 
ammonium hydrogen sulfate (Ion pair reagent).The pH was measured with EcoMet 
pH meter (Istek, Seoul, Korea). This solution was then filtered through a 0.2 μm 
hydrophilic polypropylene membrane filters (Pall Corporation, Michigan, USA) and 
degassed using ultrasonic bath (Transsonic T460, Singen, Germany) before use. The 
mobile phase for the analysis of XMP consisted of the above running buffer solution – 
methanol (94:6, v/v), mixed on-line and delivered isocratically at a flow rate of 1.0 
ml/min. The temperature of the column oven was maintained at 25 °C. Each sample 
was injected onto the column at a constant volume of 30 μl for an analysis run of 20 
min. The UV detection wavelength was set at 254 nm for the chromatographic 




3.3.1.4 Sample preparation 
 
3.3.1.4.1 Stock and working standard solution 
 
Standard IMPDH human type II enzyme was diluted with phosphate buffer saline 
(PBS) (pH 7.4) to get a desire concentration (500 nM). Standard solutions of XMP 
(2.2 mmol/L) were prepared in a reaction mixture (pH 7.4) which consisted of 0.5 
mmol/L IMP, 1 mmol/L NAD+, 40 mmol/L sodium phosphate and 100 mmol/L 
potassium chloride and stored at -20 °C. Working solutions of XMP in the reaction 
mixture were prepared by appropriate dilution of the stock solutions. 
 
3.3.1.4.2 Preparation of calibration standard 
 
A reaction mixture (150 μL) was spiked in with 10 μL each of XMP working 
solutions (1.6, 8, 16, 160, 400, 800 and 1600 μmol/L) to yield the concentrations 
corresponding to 0.1, 0.5, 1, 10, 25, 50 and 100 μmol/L) of XMP.  
 
3.3.1.4.3 IMPDH enzyme activity assay in vitro 
 
The reaction was started by adding 30 μL of IMPDH Type II standard enzyme 
solution (500 nM) to a 120 μL of reaction mixture. Different concentrations of MPA 
(0.001, 0.01, 0.025, 0.05, 0.075, 0.1 and 0.25 mg/L) were spiked into the mixture. The 
samples were incubated in a water bath at 37°C for about 2 hours. Then, the reaction 
was terminated by adding an equal volume (150 μL) of iced-cold acetonitrile (1:1, 
v/v) and protein was precipitated at -20 °C for 30 minutes. After centrifugation using 
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Avanti™ J-25 Centrifuge (Beckman Instruments, CA, USA) at 8000 rpm, 4 °C for 20 
min, and the supernatant was taken out and left overnight to evaporate the organic 
solvent. Then, the evaporated samples were frozen at -80 °C and freeze-dried for 20 
hours using FreeZone 2.5 Liter Benchtop Freeze Dry System (Labconco Corp, Kansas 
city, MO, USA). Those freeze-dried residues were dissolved in 50 μL of Milli-Q 
water and vortex-mixed. Then, 30 μL of the sample was injected into the HPLC 
column for the analysis of XMP formation.    
 




The linearity of the method was evaluated over the XMP concentration range of 0.5 
μmol/L – 1000 μmol/L. Calibration standards were freshly prepared every day during 
ongoing analysis.  
 
3.3.2.2 Intra-day and inter-day accuracy and precision 
 
Intra-day and inter-day accuracy and precision of the assay were assessed by 
performing replicate analyses of three QC sample concentrations. The procedure was 
repeated on 5 different days on the spiked standards to determine inter-day 
repeatability. Intra-day repeatability was assessed by 5 replicate assays of the QC 





In order to demonstrate the applicability of the chromatographic method for 
estimating the inhibiting effect of MPA on IMPDH activity, enzymatic assays were 
carried out according to Section 3.3. IMPDH activity was measured in vitro by a non-
radioactive assay method based on incubation of pure human IMPDH enzyme Type II 
with IMP and NAD+ followed by chromatographic determination of XMP produced. 
The above ion-paired reversed phase HPLC system was found to give an excellent 
separation of the substrate, co-substrate and product of the IMPDH enzymatic 
reaction.  
 
Calibration curves were constructed by non-weighted least squares linear regression 
of peak area of XMP versus concentration of XMP spiked into the reaction mixture. 
Linearity was assessed based on the coefficient of determination (i.e. r²) and visual 
inspection of the residual plots of the data points. Each calibration concentration was 
assayed in duplicates. Six-point calibration curves were linear over the range of 0.5 
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Figure 3.1 Calibration curve for the product XMP 
 
Chromatography of the samples shows no interfering peaks at the retention time of 
XMP. The representative chromatograms are presented in Fig. 3.2. The product XMP 
peak was separated well from the substrate IMP and co-substrate NAD+ with a total 
run time of 20 min. The retention times are NAD+ (6.5 min), IMP (7.9 min) and XMP 
(9.5 min) respectively. In the presence of IMP and NAD, a compound was eluted with 






































Spiked in pure IMP, NAD and XMP; (C) sampl  reacted with 500 nM of pure IMPDH enzyme; 
(D) A stable transplant patient sample 2 h after chronic oral dosing of MMF (500 mg b.d.) for 




Table 3.1 and Table 3.2 list the intra- and inter-day precision and accuracy for XMP 
rom these performance data, the lower limit of quantitation (LLOQ), determined as 
ymatic assay 
  
(at three different QC concentrations of 1, 50, 1000 μM). 
 
F
the lowest point on the calibration curve that could be analyzed within 20% of the 
nominal value (absolute percentage error within 20%), was 0.5 μM and upper limit of 
quantification (ULOQ) as the highest point on the calibration curve, was 1000 μM. 
The limit of detection (LOD), defined as the analyte concentration with a signal-to-
noise ratio of three, was 0.1 μM.  
 










XMP 1 1.198±0.06 4.61 19.8 
 50 2.61 -4.34 
1  
47.83±1.25 
 000 976±21.21 2.17 -2.4 
a Average of five replicates. 
 
ymatic assay  
 
 
Table 3.2 Inter-day precision and accuracy of enz
   
Concentration (uM) 
Compound a Pre






XMP 1 1.19±0.08 6.56 19 
 50 3.10 -8.48 
1  -5.44 
45.76±1.42 
 000 945.65±6.8 0.72 





3.4 DETERMINATION OF IMPDH ACTIVITY IN PATIENTS’ BLOOD 
SAMPLE (CLINICAL APPLICATION) 
 
3.4.1 Materials and methods 
 
3.4.1.1 Chemicals and reagents 
 
Inosine Monophosphate Dehydrogenase Type II (IMPDH II), Xanthosine 5’ 
monophosphate (XMP), Inosine 5’ monophosphate (IMP) and Nicotinamide adenine 
dinucleotide (NAD) were purchased from Sigma (St. Louis, MO, USA). Ficoll-
Paque™ PLUS was purchased from Amersham Biosciences AB (Uppsala, Sweden). 
All other reagents were of standard high-performance liquid chromatography (HPLC) 
or analytical grade. Lymphocytes were separated from the whole blood sample 
collected from the stable renal transplant patients. 
 
3.4.1.2 Study subjects 
 
Patients for conventional study (each patient with 6 sampling time-points) and those 
for population PK-PD modeling (each patient with 1 sampling time-point) (Table 3.3) 
were included in this study. For the conventional study group, among six adult renal 
allograft recipients transplanted 7-93 months ago who had participated in the different 
dose interval (12, 24 or 48h) measurement of PK profile, only three patients were 
included in this study of IMPDH activity because of technical difficulties in 
separation of lymphocytes and that cells count was not enough to use. 
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Table 3.3 Patients' demographics, comorbidities, concomitant immunosuppressants and 
biochemical parameters  
Different dosing regimen Patients’ Characteristics 
MMF/CsA/Steroid MMF/TAC/Steroid MMF/SRL/Steroid 
n 35 6 8 
Gende
nic Group 26C / 6M / 2I / 1O 5C / 1M 5C / 2M / 1I 
46.69±6.73(33-58) 43.67±9.44(31-56) 46.88±4.16 
68.41±15.09 (34-102) 62.68±16.28 
rbidities 32HTN / 14HL / 4DM 
e clearancea (L/hr) 2.2±1.01 (0.83-3.84) 2.51±1.33 (1.19-5.3) 
eb (μmol/L) 216.71±95.89 
/L) 14.94±10.34 (4-63) 13.17±8.61 (4-27) 
e 75.91±37.46 (33-235) 
12.29±2.34 (7.9-16.6) 11.93±2.04  11.69±1.65 (9.8-14.8) 
Red blood c ll counti (x1012/L) 4.2±0.82 (2.9-5.95) 4.18±0.59  4.21±0.55 (3.45-4.98) 
White blood cell countj (x109/L) 9.14±2.74 (4.87-16.7) 8.55±1.47 (6.93-11.69) 
Platelet count  (x10 /L) 304.67±76.87  
 M=
=Diabetes Mellitus; MMF=mycoph fetil; C ne; 






Como 6HTN / 3HL / 2DM 6HTN / 2HL 
Creatinin 2.97±1.45 (0.64-6.39) 
Serum creatinin 185.83±109.42 (85-566) 
198±109.67 
(112-413) (105-357) 
Serum albumin levelc (g/L) 37.77±5.6 (26-47) 41.33±4.23 (34-45) 38.25±2.19 (35-41) 
Total serum bilirubind (μmol 8.5±3.7 (4-14) 
Serum alkaline phosphatase
(U/L) 
Serum alanine transaminasef 
68.5±22.58 (45-102) 65±23.49 (30-110) 
(U/L) 20.37±14.73 (4-71) 14.17±5.04 (8-22) 32.5±47.48 (9-149) 
Serum aspertate 
transaminaseg (U/L) 18.86±9.2 (10-57) 16.67±4.32 (12-22) 25.5±22.88 (11-81) 










Abbreviations: M=male; F=female; I=Indian; Malay; O=other; HT
e mo
N=Hypertension; 
sA oriHL=Hyperlipidemia; DM nolate =cyclosp
TAC=tacrolimus; SRL=sirolimus; e.o.d.=every other day; o.m.=every morning; b.d.=twice a day;  
a Normal values for creatinine clearance: 5.1-8.1 L/hr 
b Normal values for serum creatinine: 53-132.6 μmol/L 
c Normal values for serum albumin: 35-50 g/L 
d Normal values for total serum bilirubin: 1.7-20.5 μmol/L 
 g/dL for males and 12-16 g/dL for females 
.3-6.2x1012/L for males and 3.8-5.5x1012/L for females 
 
.4.1.3 Sample preparation 
.4.1.3.1 Stock and working standard solution 
efer to section 3.3.1.4.1 for the stock and working standard solution for the 
determination of IMPDH enzyme activity in patients’ sample. 
e Normal values for serum ALP: 30-120 U/L 
f Normal values for serum ALT: 5-35 U/L 
gNormal values for serum AST: 5-40 U/L 
h Normal values for hemoglobin: 13.5-17.5
i Normal values for red blood cell count: 4
j Normal values for white blood cell count: 4.1-10.9x109/L 







3.4.1.3.2 Preparation of calibration standard 
 
A reaction mixture (210 μL) was spiked in with 10 μL each of XMP working 
lutions (2.2, 11, 22, 220, 550, 1100 and 2200 μmol/L) to yield the concentrations 
bes and the lymphocytes 
ere separated within 24 hours. Lymphocytes were separated using Ficoll-Paque™ 
so
corresponding to 0.1, 0.5, 1, 10, 25, 50 and 100 μmol/L of XMP.  
 
3.4.1.3.3 Preparation of lymphocytes from blood sample 
 
3 ml of blood samples were collected in EDTA vacutainer tu
w
PLUS according to the instructions of the manufacturer, Amersham Biosciences AB 
(Uppsala, Sweden). In brief, equal volume of 3 ml of EDTA anticoagulant-treated 
blood and phosphate-buffered saline (PBS) (final volume 6 ml) were mixed in a 10 ml 
test tube by drawing them in and out gently using dropper. 4 ml of Ficoll-Paque 
solution was placed in a centrifuge tube. Then, the 6ml of diluted blood sample was 
layered carefully on the Ficoll-Paque solutions. The sample was then centrifuged at 
1700 rpm for 30 minutes. The upper layer of plasma which is essentially free of cells 
was drawn off using a clean Pasteur pipette and saved for later use. The lymphocytes 
layer at the interface was undisturbed and transferred to a clean centrifuge tube. 3 
volumes (6 ml) of phosphate-buffered saline were added to the lymphocytes in the 
centrifuge tube. The cells were suspended by gently drawing them in and out of 
dropper and centrifuged at 400 rpm for 10 minutes. After that the supernatant was 
removed. An aliquot was used for cell counting using Haemacytometer (Neubauer 
Improved Brand, Germany). The rest of the cells were diluted with PBS to get the 
desired cell count (1×106 cell lysates) and kept in -80 °C until analysis. After thawing 
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the cells for sample preparation, the insoluble fragments of disrupted cells were 
removed by centrifugation at 1000 g for 2 minutes. The supernatant portions were 
used for enzymatic assay and protein content assay. 
 
3.4.1.3.4 Cell counting 
 
Clean and dry haemacytometer with the cover slip was prepared. 40 μL of 0.4% (w/v) 
f Trypan blue was added to the 10 μL of cell suspension (i.e. a 1:5 dilution of the 
 
o
cells). Those cells and trypan blue solution were mixed well by gently pipeting up and 
down a few times. 10 μL of cell mixture was loaded on to one chamber and the cells 
were counted manually under the binoculars microscope (American Optical A.O. 120 
series, Binocular, USA). 
 
Calculation of cell count
 
suspension original of VolumefactorDilution 410
counted) square of .(no 4
squares 4in  cells of .no TotalCounts Viable Total = ×××
(Equation 3.1) 
ination of protein concentration in cell lysates 
structions of the 





The protein concentration was determined according to in
m
was used for the determination of protein content of cell lysates. Dye reagent was 
prepared by diluting 1 part Dye reagent concentrate with 4 parts distilled water. 
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Bovine serum albumin (linear range 0.2 to 0.9 mg/ml) was prepared from the standard 
bovine serum albumin. 100 μL of each standard and sample solution was pipetted into 
a clean, dry test tube. 5 ml of diluted dye reagent was added to each tube and 
vortexed. The mixture was incubated at room temperature for at least 5 minutes. The 
absorbance was measured at 595 nm using spectrophotometer. The protein 
concentration in each cell lysate sample was estimated by reference to the calibration 
curve generated from standards measured along with the samples. 
 
3.4.1.4 Determination of IMPDH activity in lymphocytes sample 
 modified from 
lander et al. (2001) [33] and Brouwer et al. (2006) [38] by using isocratic ion-pair 
 
Method for the determination of IMPDH activity was adopted and
G
reversed phase HPLC. 100 μL of cell lysates were added to 120 μL of reaction 
mixture and incubated at 37 °C for 2 hours. Then, the reaction was terminated by 
adding equal volume 220 μL of iced-cold acetonitrile and protein was precipitated at -
20 °C for 30 minutes. After centrifugation using Avanti™ J-25 Centrifuge (Beckman 
Instruments, CA, USA) at 8000 rpm, 4 °C for 20 min, and the supernatant was 
transferred and evaporated the organic solvent overnight. Then, the evaporated 
samples were frozen at -80 °C and freeze-dried for 20 hours using FreeZone 2.5 Liter 
Benchtop Freeze Dry System (©Labconco Corp, Kansas city, MO, USA). Those 
freeze-dried residues were dissolved in 50 μL of Milli-Q water and vortex-mixed. 
Then, 30 μL of the sample was injected into the HPLC column for the analysis of 
XMP formation in cell lysates. The specific IMPDH enzyme activity was expressed in 
nmol/h/mg protein. The enzyme activity was calculated by (amount of product 




In patients for the population PK-PD modeling who were on MMF for more than 3 
onths, a wide inter-individual variation of IMPDH activity was observed (Fig 3.3), 
mary of the IMPDH activity obtained in RTxRs for conventional study and patients for 
rmacokinetic and pharmacodynamic study following chronic oral dosing of MMF for 
more than 3 months 
 Patients for conventional study 
Population pharmacokinetic and 
pharmacodynamic study 
m
overall ranging from 5.15 to 55.03 (mean±SD 25.43±12.03) nmol/h/mg protein (See 




Mean±SD 29.34±9.99 25.43±12.03 
CV % 34% 47.3% 




















      
Figure 3.3 Inter-individual variability of IMPDH activity (nmol/h/mg protein) in patients for 
population pharmacokinetic and pharmacodynamic study (n=46) 
 
as a significant negative correlation between logarithmic MPA plasma 
In patients for conventional study (n=3, each patient with six sampling points), there 
w
concentration, either total or free, and IMPDH activity in lymphocytes (r2=0.7351 and 
0.6761, both P<0.01), but no statistical significant correlation was found between 
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logarithmic MPAG plasma concentration, either total or free, and IMPDH activity in 
lymphocytes (r2=0.1506 and 0.0959) (See Fig 3.4 to 3.7). Similarly, in patients for 
population PK-PD modeling (n=46, each patient with one sampling point), a 
significant correlation was found between logarithmic MPA plasma concentration, 
either total or free, and IMPDH activity in lymphocytes (r2=0.30396 and 0.62964, 
both P<0.01) and no correlation was observed between logarithmic MPAG plasma 
concentration, either total or free, and IMPDH activity in lymphocytes (r2=0.05465 
and 0.14933) (See Fig 3.8 to 3.11). However, in patients for both conventional study 
and population PK-PD modeling (n=49), there was a statistical significant correlation 
logarithmic MPA plasma concentration, either total or free, and IMPDH activity in 
lymphocytes (r2=0.4946 and 0.6106 respectively, both P<0.01) and a weaker 
correlation was seen between logarithmic MPAG plasma concentration, either total or 











Figure 3.4 IMPDH activity in lymphocytes Vs Total MPA plasma concentration (mg/L) in 
plasma in stable renal transplant patients for the conventional study after chronic oral dosing of 





Figure 3.5 IMPDH activity in lymphocytes Vs Free MPA plasma concentration (mg/L) in plasma 
in stable renal transplant patients for the conventional study after chronic oral dosing of MMF 







Figure 3.6 IMPDH activity in lymphocytes Vs Total MPAG plasma concentration (mg/L) in 
plasma in stable renal transplant patients for the conventional study after chronic oral dosing of 




Figure 3.7 IMPDH activity in lymphocytes Vs Free MPAG plasma concentration (mg/L) in 
plasma in stable renal transplant patients for the conventional study after chronic oral dosing of 








Figure 3.8 IMPDH activity in lymphocytes Vs Total MPA plasma concentration (mg/L) in 
plasma in stable renal transplant patients for population PK-PD modeling after chronic oral 
dosing of MMF for more than 3 months (n=46, each patient with 1 sampling point at 0, 2 or 6 h 




Figure 3.9 IMPDH activity in lymphocytes Vs Free MPA plasma concentration (mg/L) in plasma 
in stable renal transplant patients for population PK-PD modeling after chronic oral dosing of 








Figure 3.10 IMPDH activity in lymphocytes Vs Total MPAG plasma concentration (mg/L) in 
plasma in stable renal transplant patients for population PK-PD modeling after chronic oral 
dosing of MMF for more than 3 months (n=46, each patient with 1 sampling point at 0,2 or 6 h 





Figure 3.11 IMPDH activity in lymphocytes Vs Free MPAG plasma concentration (mg/L) in 
plasma in stable renal transplant patients for population PK-PD modeling after chronic oral 
dosing of MMF for more than 3 months (n=46, each patient with 1 sampling point at 0, 2 or 6 h 





Figure 3.12 IMPDH activity in lymphocytes Vs Total MPA plasma concentration (mg/L) in 
plasma in stable renal transplant patients for both conventional study and for population PK-PD 




Figure 3.13 IMPDH activity in lymphocytes Vs Free MPA plasma concentration (mg/L) in 
plasma in stable renal transplant patients for both conventional study and for population PK-PD 







Figure 3.14 IMPDH activity in lymphocytes Vs Total MPAG plasma concentration (mg/L) in 
plasma in stable renal transplant patients for both conventional study and for population PK-PD 




Figure 4.15 IMPDH activity in lymphocytes Vs Free MPAG plasma concentration (mg/L) in 
plasma in stable renal transplant patients for both conventional study and for population PK-PD 






Several sample preparation methods were attempted to get the high sensitivity to 
detect the reaction product XMP. In this study, determination method for IMPDH 
enzyme activity using isocratic ion-pair reversed phase HPLC was developed by 
modifying and optimizing the existing procedures from Glander et al. (2001) and 
Brouwer et al. (2006) [33, 38], which include the reaction condition such as time for 
incubation and stopping reaction and the sample preparation such as protein 
precipitation, freeze-drying and thawing of the white blood cells. The inter- and intra-
day coefficients of variation were all less than 7% at three different QC concentration 
of XMP with the accuracy varied from -8.48 to 19.8%.  
 
This assay was possible to detect the IMPDH activity based on XMP produced in 49 
out of 56 stable renal transplant patients’ lymphocytes in our in vivo study (n=3 for 
conventional study and n=46 for population PK-PD modeling). Thus, it is suggested 
to use this chromatographic method for the routine measurement of IMPDH enzyme 
activity in stable renal transplant patients. However, the assay was not sensitive 
enough to some patients. It could be due to the very low enzyme activity in those 
patients themselves.  
 
In each assay performed, higher concentrated mononuclear cell (MNC) lysates were 
used as the product XMP was not detectable with cell concentrations of (3x105 viable 
cell) proposed by Brouwer et al. [38] and (2.5x108±1x106 cells/L) proposed by 
Griesmacher et al. [30] . However, the concentration (1x106 cells/ml lysate) of 
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lymphocytes presently used was low compared to cell concentration used in the other 
reported methods (4x106 cells/ml lysate) and (1x107 cells/ml lysate) [30, 33, 60, 61]. 
 
For lymphocyte isolation, MNC samples were stored as freeze –dried pellet in 
Brouwer et al. method. In this study, to save one freeze drying step, MNC samples 
were stored in liquid form for future assay. 3 ml of blood for each sample was used to 
separate lymphocytes. Approximately 4-5 x 106 cells / ml lysate was produced from 
each blood sample and the MNC lysate were diluted with PBS to get a desired cell 
concentration.  
 
Brouwer’s method reported two freeze-drying steps for their sample preparation with 
very low concentration to get more concentrated cells of MNC lysate, but the 
drawback of this procedure is that it takes more steps for preparation to get the freeze-
dried pellets and it might have longer sample preparation time. (See Table 3.5) 
 
Previous studies have shown large intra-individual and inter-individual differences in 
IMPDH activity and the coefficient of variation was approximately 33.93-38.78%. In 
agreement with other investigators we observed a high variability of IMPDH activity 
in patients (see table 1.2) [33, 34, 39]. MPA has been washed out during preparation 
to obtain platelets free MNC lysate which lies between plasma layer and Ficoll-Paque 
Plus that is used for lymphocyte separation. It could be the reason why that there is a 
minor increase of IMPDH activity in MNC lysate is seen in some patients within our 
own group of patients. Because of dilution of sample, our assay may lead to an 
underestimation of the inhibition of IMPDH activity by MPA in MMF treated 
patients. 
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A simple and reliable method was developed and validated for the quantification of 
formed product XMP in cell lysates supplemented with IMP and NAD+. This method 
is rapid, robust and sensitive enough to apply successfully for determination of 
IMPDH activity in mononuclear cells. 
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Table 3.5 Summary of sample preparation and results of pharmacodynamic study of MMF in reported literatures 




















40 mmol/L sodium 
phosphate buffer 
(pH 7.4) 
100 mmol/L KCL 
0.5 mmol/L NAD 
1 mmol/L IMP 
-Incubate 40 μL of erythrocyte 
lysate and reaction mixture at 
37°C for 2 h 
-Terminate the reaction with 25 






















1 g b.i.d 
CsA 5 ml 40 mmol/L sodium 
phosphate buffer 
(pH 7.4) 
100 mmol/L KCL 
0.5 mmol/L NAD 
1 mmol/L IMP 
- Incubate 50 μL of MNC lysate 
and 120μL reaction mixture at 
37°C for 2.5 h 
-Terminate the reaction with 20 
μL of 4 mol/L of ice-cold 
perchloric acid 
-protein precipitate 
-neutralize the supernatant with 
10 μL of 5 mol/L potassium 
carbonate 
-store mixture for at least 30 min 
at -80°C 
-thaw, centrifuge and store at -











0.6 – 24.3 




8.4 – 21.2 nmol/h/mg protein 
 
 









NA 30 ml 80 mmol/L sodium 
phosphate buffer 
(pH 7.4) 
200 mmol/L KCL 
6 mmol/L NAD 
6 mmol/L IMP 
- Incubate 100 μL of MNC lysate 
and 120μL reaction mixture at 
37°C for 2.5 h 
-Terminate the reaction with 25 
μL of 2.5 mol/L of cold 
perchloric acid 
-neutralize the supernatant with 
50 μL of 3 mol/L di-potassium 
phosphate (>pH 7.2) 
-centrifuge, frozen  and store at -
25°C for analysis 
4x106 
cells/ml  




        Table 3.5 Continued 
Stable RTxR=1 1 g b.i.d. CsA/Steroid 5 ml 40 mmol/L sodium 
phosphate buffer 
(pH 7.4) 
100 mmol/L KCL 
0.5 mmol/L NAD 
1 mmol/L IMP 
- Incubate 50 μL of MNC lysate 
and 120μL reaction mixture at 
37°C for 2.5 h 
-Terminate the reaction with 20 
μL of 4 mol/L of ice-cold 
perchloric acid 
-protein precipitate 
-neutralize the supernatant with 
10 μL of 5 mol/L potassium 
carbonate 
-store mixture for at least 30 min 
at -80°C 
-thaw, centrifuge and store at -













10.2 nmol/h/mg prot 
 
Minimal= 
1.9 nmol/h/mg prot 
 
Mean= 
6.52 nmol/h/mg prot 
[35] 
Stable RTxR=6 1 g b.i.d. NA 5 ml 40 mmol/L sodium 
phosphate buffer 
(pH 7.4) 
100 mmol/L KCL 
0.5 mmol/L NAD 
1 mmol/L IMP 
- Incubate 50 μL of MNC lysate 
and 120μL reaction mixture at 
37°C for 2.5 h 
-Terminate the reaction with 20 
μL of 4 mol/L of ice-cold 
perchloric acid 
-protein precipitate 
-neutralize the supernatant with 
10 μL of 5 mol/L potassium 
carbonate 
-store mixture for at least 30 min 
at -80°C 
-thaw, centrifuge and store at -
























40 mmol/L sodium 
phosphate buffer 
(pH 7.4) 
100 mmol/L KCL 
0.5 mmol/L NAD 
1 mmol/L IMP 
-Incubate 40 μL of erythrocyte 
lysate and reaction mixture at 
37°C for 2 h 
-Terminate the reaction with 25 










<7 – 15 nmol/h/mg prot 
[34] 
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1 g b.i.d. 









CsA/Steroids 7.5 ml 10 µL NAD (final 
conc. 0.25 mmol) 
10 µL IMP (final 
conc. 0.25 mmol  
-Incubate in a water bath at 37°C 
for 30 minutes 
_Quench the reaction with 0.15 
mL of 4 mol of  perchloric acid 
-Centrifuge and heated at 100°C 
for 60 min 
-Cool to room temperature and 
add  0.7–0.9 mL 4 M KOH (pH 
2–3) 
-Vortex the suspension and 
centrifuge 




















































        Table 3.5 Continued 
Stable 
RTxR=18 
1 g b.i.d. CsA/with or 
without 
Steroids 
5 ml 40 mmol/L sodium 
phosphate buffer 
(pH 7.4) 
100 mmol/L KCL 
0.5 mmol/L NAD 
1 mmol/L IMP 
- Incubate 50 μL of MNC lysate 
and 120μL reaction mixture at 
37°C for 2.5 h 
-Terminate the reaction with 20 
μL of 4 mol/L of ice-cold 
perchloric acid 
-protein precipitate 
-neutralize the supernatant with 
10 μL of 5 mol/L potassium 
carbonate 
-store mixture for at least 30 min 
at -80°C 
-thaw, centrifuge and store at -














Predose IMPDH  
8.63±4.29 nmol/h/μg prot 
 
Maximal IMPDH 
13.8±4.66 nmol/h/μg prot 
 
Minimal IMPDH 














phosphate buffer  
66.7 mmol/L KCL 
1.7 mmol/L NAD 
0.16 mmol/L IMP 
0.16 mmol/L DTT 
- Incubate freeze-dried pellet 
MNC lysate and 120μL reaction 
mixture at 37°C for 2h 
-Terminate the reaction with three 
volume of ice-cold methanol 
-protein precipitate at -20°C for 
30 min 
-centrifuge and freeze dry over 
night   
-Dissolve freeze-dried residue 
with 200μL of 40 mmol/L 
potassium phosphate buffer 
containing 1.7 g/L TBAS pH 3 
-Centrifuge and inject the 









Abbreviation : MMF=Mycophenolate mofetil ; CsA=Cyclosporine ; NA=Data not available ; b.i.d.=twice a day; RTxR=Renal Transplant Recipient; C0=trough plasma concentration; Cmin=minimum 
plasma concentration; Cmax=maximum plasma concentration; AUC=Area under the plasma concentration-time curve; MNC=mononuclear cell; IMP=Inosine 5’-monophosphate; NAD+=nicotinamide 









MPA is a potent, selective, uncompetitive, and reversible inhibitor of IMPDH and 
thus, exerts potent cytostatic effects on both T and B proliferating lymphocytes by 
inhibiting the de novo pathway of guanosine nucleotides synthesis. MPA is 
extensively metabolized by UDP-glucuronosyltransferases in the liver, 
gastrointestinal tract, and possibly kidney, mainly into the inactive metabolite MPAG 
that is primarily excreted by the kidneys, and partly by biliary secretion into the small 
intestine which also undergoes enterohepatic circulation by being converted back to 
MPA which, in turn, is re-absorbed back into blood circulation. The parent drug MMF 
was undetectable in plasma following its oral administration, confirming the rapid 
conversion of MMF to MPA [10, 64]. 
 
The standard immunosuppressive regimen after organ transplantation is the use of 
combination therapy with several immunosuppressants, typically a primary 
immunosuppressant (calcineurin inhibitor: cyclosporine or tacrolimus) together with a 
corticosteroid (prednisolone) and an adjunctive agent (azathioprine or MMF, or 
sirolimus). MMF is widely used in combination with either cyclosporine or tacrolimus 
or sirolimus for rejection prophylaxis in renal and heart transplant patients. The use of 
mycophenolate mofetil (MMF) has largely replaced that of the purine antagonist 
azathioprine in post-transplant immunosuppressant therapy in kidney transplant 
recipients [63]. After an initial period of graft stabilization, the trend in transplant 
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medicine is to reduce immunosuppression by 1) elimination of corticosteroid, 2) 
reduction or elimination of calcineurin inhibitor, or 3) replacement of a calcineurin 
inhibitor with sirolimus in patients who are particularly sensitive to the nephrotoxicity 
of calcineurin inhibitors [52, 55]. 
 
At present, MMF is administered as a fixed dose in local hospitals and TDM is not 
done routinely, although dosage adjustment could be made in relation to clinical 
effects and measured trough concentration in plasma. Based on clinical experience to 
date, the recommended dosage of MMF for prophylaxis of organ rejection in renal 
transplant patients is 2 to 3 g per day, given in 2 to 3 divided doses. However, this 
recommendation is based on clinical trials carried out in the Western population [65, 
66]. In the Chinese renal transplant population, MMF given at 1.5 g per day is 
comparable in efficacy and associated with reduced occurrence of adverse effects 
(diarrhoea, vomiting, abdominal pain, leucopenia, tissue invasive cytomegalovirus 
(CMV) infection) compared to that given at 2 g per day [67, 68]. A local trial 
conducted in Singapore General Hospital has also suggested the need for dosage 
reduction in the Asian population to minimize risk of adverse effects. Yau et al. 
proposed that MMF should be dosed based on total body weight rather than a fixed 
dose regimen in renal transplant patients. This study was done on the Asian renal 
transplant patients in Singapore General Hospital [69]. 
 
The PK characteristics of both total and free MPA and MPAG have been investigated 
in adult and pediatric organ transplant recipients [35, 45, 48-51, 70, 71]. However, 
none of these studies report any PD profile of MPA. Most of these studies are focused 
on western (Caucasians) populations but have limited information on Asian subjects. 
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Although several studies have investigated the concentration-time profile of total 
MPA in Asians, mostly in Chinese, none of those studies investigate any kinetic and 
PD profiles of free MPA and its major metabolites MPAG [46, 47, 67, 68]. There are 
also a few studies on the PK of total MPA and its IMPDH activity in Caucasian [35, 
36, 48].  To have a better understanding of variability in PK of MPA and its activity 
encountered in renal transplant patients, information is needed about the profile of 
free MPA, which is pharmacologically active, and its main metabolite MPAG, which 
is pharmacologically inactive but plays a significant displacement effect on the 
binding of MPA to human serum albumin at clinically relevant concentration.  
 
Several studies have reported an exposure to MPA in patients receiving 
mycophenolate mofetil in combination with cyclosporine and corticosteroids. 
Nowadays, sirolimus is used as a replacement of calcineurin inhibitor in patients who 
are particularly sensitive to the nephrotoxicity of calcineurin inhibitor [52, 55].  There 
are a few data on the PK of MPA in the presence of sirolimus, but to our knowledge 
no study has been reported on any PD profile of MPA during sirolimus therapy [3, 52, 
55]. 
 
Therefore, this study aimed to investigate the pharmacokinetic and pharmacodynamic 
characteristics of both total and free MPA and MPAG in plasma in Asian stable renal 






4.2 Materials and methods 
 
4.2.1 Pharmacokinetic study of total MPA and MPAG in plasma 
 
MPA is almost completely (>99%) bound to plasma albumin in humans. In rats, the 
erythrocytes/plasma ratio is as low as 0.1:0.15 and the bound fraction of MPA in 
plasma is 98%. Therefore, plasma is the matrix of choice for measurement of MPA 
concentrations [72]. 
 
4.2.1.1 Chemicals and reagents 
 
MPA was obtained from Fluka Chemie (Buchs, Switzerland). MPAG was a generous 
gift from Roche Bioscience (Palo Alto, CA, USA). All other reagents were standard 
high-performance liquid chromatography (HPLC) or analytical grade. Pooled blank 
human plasma was obtained from the blood bank of the National University Hospital 
(NUH), Singapore. Blank human urine was from a single healthy individual after an 
overnight fast. 
 
4.2.1.2 Study subjects 
 
This project is designed as a prospective, open-labelled, single-centre study conducted 
in Singapore General Hospital (SGH). This study was approved by the Ethics 
Committee of SGH and written informed consent was obtained from all the patients 
participated in this study. 
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Patients for inclusion in the study were follow up cases of adult renal transplant 
recipients from the Department of Renal Medicine, SGH and were recruited 
consecutively into the study. These include stable adult patients who have been on 
MMF for at least 3 months prior to recruitment into the study.  
 
4.2.1.2.1 Inclusion criteria 
 
They include: 
1. Adult stable renal transplant recipients who are on MMF in combination with 
Cyclosporine (CsA) -based or Tacrolimus (TAC) or Sirolimus (SRL) - based 
and Corticosteroids immunosuppressive triple regimens; 
 
2. Stable patients (those who have been receiving MMF before they were 
recruited into the study) who are on the same doing regimen of MMF, either 
CsA or Tacrolius or Sirolimus, for at least 1 week before PK investigations; 
 
3. Written informed consents from the patients were obtained beforehand in 
order to participate in the study.  
 
4.2.1.2.2 Exclusion criteria 
 
They include: 
1. Patients who have history of severe GI disorders that interfere with their 
ability to receive or absorb medication administered orally and those who have 
history of severe diarrhoea (> 5 watery stools per day) were excluded to 
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participate in the study.  
 
Six patients were selected to be participated for this conventional study. In this group 
of patients (n=6), the pharmacokinetics of MPA and its major metabolite MPAG and 
the pharmacodynamics of MPA (IMPDH activity) within the dose intervals were 
investigated. Six adult renal allograft recipients transplanted 7-93 months ago who 
have participated in the 12-h dose interval measurement of PK profile. A summary of 
characteristics of patients is shown in Table 4.1. 
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Table 4.1 RTx Patients' demographics, comorbidities, concomitant immunosuppressants 
and biochemical parameters for the conventional study 
Patient characteristics LCLG TCKO LWH CSLA GTH VS Mean±SD (range) 
Gender M M M F M F 4M/2F 
Ethnic group C C C C C I 5C/1I 
Age (Yr) 30 58 39 33 48 39 40±11 (30-58) 
Weight (Kg) 66 52.3 57 43.2 57.9 51.3 54.62±7.65 (43.2-66) 
Comorbidities  HTN HL HTN HTN HTN 4HTN/1HL 
Concomitant 
immunosuppressants        










 b.d.  
SRL (mg) 1 b.d. 1 o.m. 1 o.m. 1 b.d. 1 b.d. 1 b.d.  
Prednisolone (mg) 10 mg  o.m. 
10 mg  
o.m. 
10 mg  
 o.m. 











(μmol/L) 320 231 357 256 228 125 
252.83±81 
(125-357) 
Serum albumin levelc 
(g/L) 38 35 37 36 27 43 
36±5.22 
(27-43) 
Total serum bilirubind 












transaminaseg (U/L) 16 81 19 14 27 23 
30±25.42 
(14-81) 
Hemoglobinh (g/dl) 10.4 10.2 11.8 9 8.2 14.2 10.63±2.14 (8.2-14.2) 
Red blood cell counti 
(x1012/L) 4.08 3.45 4.38 3.45 3.17 5.1 
3.94±0.73 
(3.17-5.1) 
White blood cell countj 
(x109/L) 8.51 9.05 7.79 7.7 6 8.36 
7.9±1.06 
(6-9.05) 
Platelet countk (x109/L) 202 162 228 233 229 205 209.83±26.86 (162-233) 
Abbreviations: M=male; F=female; C=Chinese; I=Indian; HTN=hypertension; HL=hyperlipidemia; 
MMF=mycophenolate mofetil; SRL=sirolimus; e.o.d.=every other day; o.m.=every morning; b.d.=twice a 
day;  
a Normal values for creatinine clearance: 5.1-8.1 L/hr    
b Normal values for serum creatinine: 53-132.6 μmol/L    
c Normal values for serum albumin: 35-50 g/L     
d Normal values for total serum bilirubin: 1.7-20.5 μmol/L    
e Normal values for serum ALP: 30-120 U/L     
f Normal values for serum ALT: 5-35 U/L     
g Normal values for serum AST: 5-40 U/L     
h Normal values for hemoglobin: 13.5-17.5 g/dL for males and 12-16 g/dL for females  
i Normal values for red blood cell count: 4.3-6.2x1012/L for males and 3.8-5.5x1012/L for females 
j Normal values for white blood cell count: 4.1-10.9x109/L   
k Normal values for platelet count: 140-450x109/L    
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4.2.1.3 Sample collection 
 
A duplicate set of venous blood samples (2 x3 ml) was collected on a single day (at 
least 3 months after the start of MMF therapy) at time-points: pre-dose 0 (before 
morning dose), 0.5, 1, 1.5, 2 and 6 hours after morning dose. All patients were in 
steady-state stable condition which assuming that MPA plasma concentration at τ (12, 
24 or 48 h) postdose was equal to predose MPA plasma concentration (C0) for q.d. 
(once a day), b.i.d. (2 times a day) and q.o.d. (every other day) dosing. All six patients 
received Sirolimus (RAPA), MMF (CellCept®) and Steroids for 12 h, 24 h or 48 h.  
 
Urine sample was collected over 12-h, 24-h or 48-h period and the total volume of 
urine collected was recorded and a duplicate of 5 ml aliquots of urine (2 x 5 ml) was 
stored in -20° C until HPLC analysis. 
 
4.2.1.4 Sample Preparation 
 
4.2.1.4.1 Stock and working standard solutions 
 
Standard stock solutions of MPA (1000 mg/l) and MPAG (5000 mg/l) were prepared 
in methanol and stored at -20° C. These stock solutions were diluted to prepare 
working solutions in methanol-water (8:2, v/v) to yield concentrations from 5 to 500 





4.2.1.4.2 Calibration standards of plasma sample 
 
Aliquots of 100 μl of blank human plasma were spiked with 10 μl each of the MPA 
(5, 10, 50, 100, 250 and 400 mg/l) and MPAG (100, 250, 500, 2000, 3000 and 4000 
mg/l) working solutions to yield to yield spiked plasma concentrations corresponding 
to 0.5, 1, 5, 10, 25 and 40 mg/l for MPA and 10, 25, 50, 200, 300, 400 mg/l for 
MPAG receptively. These calibration standard samples were vortex-mixed for 1 min 
and allowed to equilibrate at room temperature for 10 to 20 minutes. Subsequently, 
protein precipitation was carried out by adding 100 μl of acetonitrile (i.e. 1:1 of 
sample and acetonitrile) to each of the above samples, followed by vigorous vortex-
mixing for 2 minutes. The mixtures were then left to stand at room temperature for 
10-15 minutes, after which they were centrifuged at 8000 rpm for 20 minutes at 4° C 
using an Avanti™ J-25 Centrifuge (Beckman Instruments, CA, USA). Aliquots of 20 
μl of the clear supernatant were then injected onto the HPLC system for analysis. 
 
4.2.1.4.3 Plasma sample preparation 
 
The 3 ml each of blood samples were freshly collected in EDTA Vacutainer tubes and 
centrifuged at 3000 rpm for 10 minutes at 25° C using a Universal 32R centrifuge 
(Hettich AG, Bach, Switzerland) to separate plasma which was transferred to 
polypropylene tubes and stored at -20° C until analysis. For analysis, the plasma 
samples were thawed and an aliquot of 100 μl each was then treated using the 
procedure described above for the calibration standards of plasma samples, except 
that the spiking of 10 μl each of MPA and MPAG working solutions was replaced by 
the spiking of 20 μl of methanol-water (8:2, v/v) for standardization. The 
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concentrations of MPA and MPAG in the plasma samples obtained were calculated 
by reference to calibration curves generated from calibration standards analyzed along 
with these samples.  
 
4.2.1.4.4 Calibration standards of urine samples 
 
Aliquots of 25 μl of blank human urine were spiked with 25 μl each of the MPA (5, 
10, 25, 50, 100, 250 and 500 mg/l) and MPAG (20, 50, 100, 250, 500, 2000 and 4000 
mg/l) working solutions to yield spiked urine concentrations corresponding to 5, 10, 
25, 50, 100, 250 and 500 mg/l for MPA, and 20, 50, 100, 250, 500, 2000 and 4000 
mg/l for MPAG, respectively. These calibration standard samples were vortex-mixed 
for 1 min and allowed to equilibrate at room temperature for 10 - 15 minutes. The 
samples were then diluted to 250 μl with water and vortex-mixed for 2 minutes. 
Aliquots of 20 μl of the diluted solutions were injected onto the HPLC system for 
analysis. 
 
4.2.1.4.5 Urine sample preparation 
 
Urine sample was collected from incrementally over dosing intervals (τ) 12, 24 or 48h 
from the time MMF was administered to the time the next dose was administered. The 
total volume of urine collected over the dosing interval period was recorded and 5 ml 
aliquot was removed and stored at -20° C until analysis.  
 
For analysis, the urine sample was thawed and an aliquot of 25 μl was then treated 
using the procedure described above for the calibration standards of urine samples, 
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except that the spiking of 25 μl each of MPA and MPAG working solutions was 
replaced by the spiking of 50 μl of methanol-water (8:2, v/v) for standardization. The 
concentrations of MPA and MPAG in the urine sample were calculated by reference 
to calibration curves generated from calibration standards that were analyzed along 
with the urine sample. 
 
4.2.1.5 Determination of total MPA and MPAG in plasma and urine samples 
 
A reversed-phase high-performance liquid chromatographic method was used to 
determine the concentration of total MPA and its major metabolite MPAG in stable 
renal transplant patients’ plasma and urine samples as described in Section 3.1. 
 
4.2.2 Protein binding study of free MPA and MPAG in plasma 
 
Most drugs bind to the two major serum proteins; albumin and α1-acid glycoprotein 
α1-AGP. The extent to which binding occurs varies and depends on the affinity 
between drug and protein, the drug concentration, and the concentration of protein 
and the presence of other substances which either compete with drug for binding sites 
or displace it through allosteric effects. Any one or all of these factors can vary as a 
function of genetics, age, disease and drug administration [11]. 
 
MPA is tightly and extensively bound to human serum albumin, with a range of 
protein binding of 97% to 99% in patients with normal renal and liver function. On 
the basic of in vitro investigations, free MPA concentrations are presumed to be 
responsible for inhibition of human IMPDH and suppression of proliferation in 
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mitogen stimulated lymphocytes [41, 65]. The primary metabolite of MPA is the 
phenolic glucuronide 7-0-MPAG. Two further metabolites have been identified in 
humans, namely the acyl glucuronide (AcMPAG) and the phenolic glucoside of 
MPA. Of these three metabolites, only the acyl glucuronide is capable of inhibiting 
human IMPDH-II in vitro [41]. 
 
Free or unbound drug, which is not bound to plasma proteins is pharmacologically 
active and therefore more closely related to efficacy and toxicity than total blood or 
plasma concentrations [11]. 
 
4.2.2.1 Chemicals and reagents 
 
Mycophenolic acid (MPA) was obtained from Fluka Chemie (Buchs, Switzerland). 
Metabolite MPA-glucuronide (MPAG) and carboxybutoxy ether of MPA (MPAC) 
were a generous gift from Roche Bioscience (Palo Alto, CA, USA). All other reagents 
were standard high-performance liquid chromatography (HPLC) or analytical grade. 
Pooled blank human plasma was obtained from the blood bank of the National 
University Hospital (NUH), Singapore. 
 
4.2.2.2 Study subjects 
 
The same patients of study population for the conventional study (Section 4.2.1.2) 








Vivaspin -2- ultrafiltration devices (Vivascience Inc., Hannover, Germany), each 
consisting of a membrane with 2000 Da molecular weight cutoff (MWCO), were used 
in this study to improve protein removal. 500 μL of thawed plasma from each sample 
was incubated in a shaking water bath at 37 °C for 1 h and these plasma samples were 
added to each ultrafiltration device and centrifuged at 3000 g for 20 min at 37 °C 
using Avanti™ J-25 Centrifuge (Beckman Instruments, CA, USA) to obtain 
ultrafiltrates. This allowed for the direct injection of protein-free ultrafiltrates into the 
HPLC for analysis without further extraction procedures. 
 
4.2.2.3.2 Calibration standard of ultrafiltrate sample and patients’ sample 
 
Standard stock solutions of MPA (100 mg/L), MPAG (5000 mg/L) and the internal 
standard (I.S.), MPAC (1000 mg/L) were prepared in methanol and stored at -20°C. 
Working solutions of MPA, MPAG and MPAC in methanol-water (8:2, v/v) were 
prepared by appropriate dilution of the stocks solutions. 
 
For the calibration standards, aliquots of 150 μL of blank ultrafiltrate from pooled 
blank human plasma were spiked with 10 μL each of the MPA, MPAG and MPAC 
working solution to yield spiked ultrafiltrate concentrations from 0.005 mg/L to 0.05 
mg/L for MPA, from 1 mg/L to 150 mg/L for MPAG and 15 mg/L for MAPC. 
 
 73
For the patients’ sample free drug quantification, 500 μL of thawed plasma from each 
sample was incubated in a shaking water bath at 37°C for 1 h and subject to 
ultrafiltration. The ultrafiltrate collected (150 μl) was treated as above for the 
calibration standards, except that 20 μl of methanol-water (8:2, v/v) was spiked in 
place of 10 μl each of MPA and MPAG working solutions. The free MPA and MPAG 
in ultrafiltrate samples were calculated by reference to calibration curves generated 
from calibration standards analyzed along with these samples.  
 
4.2.2.4 Determination of free MPA and MPAG in ultrafiltrate 
 
A reversed-phase high-performance liquid chromatographic method was used to 
determine the concentration of free MPA and its major metabolite MPAG in stable 
renal transplant patients’ ultrafiltrates as described in Section 3.2. 
 
4.2.3 Pharmacodynamic study of MPA 
 
Pharmacodynamic (PD) monitoring measures the biological response to a drug, which 
alone or coupled with pharmacokinetics provides a novel method for optimization of 
drug dosing [73]. Pharmcodynamic monitoring of the biological effect of 
immunosuppressive drug provides an alternative to traditional therapeutic drug 
monitoring. This approach has advantages over the measurement of drug 
concentration especially in multiple drug therapy, where assessment of the 
appropriate therapeutic concentration range may be difficult [74].  
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Mycophenolic acid is an active metabolite of pro-drug mycophenolate mofetil and a 
selective, reversible and noncompetitive inhibitor of IMPDH. This drug is reported to 
provide effective immunosuppression by inhibiting inosine monophosphate 
dehydrogenase (IMPDH) which controls the first step in guanosine 5’ triphosphate 
(GTP) biosynthesis from either the de novo synthetic pathway or salvage pathway 
[32]. IMPDH catalyzes the NAD+-dependent oxidation of IMP to XMP, an 
intermediate metabolite in the synthesis of GTP, and is considered to be the rate-
limiting enzyme in the de novo guanylate biosynthetic pathway[30]. Compared to 
other cell types, the synthesis of purine nucleotides in activated lymphocytes is 
strongly dependent on the de novo pathway. Therefore, the antiproliferative activity of 
MPA shows selectivity against lymphocytes [39]. 
 
In most human cells IMPDH exists as two isoforms derived from different genes 
designated type I and type II. Type I is constitutively expressed in normal leukocytes 
and rested lymphocytes, whereas type II is up-regulated in neoplastic, replicating cells 
and activated lymphocytes [30]. 
 
An optimal strategy for monitoring has not been established for MMF in renal 
transplantation. Clinical investigations of the pharmacokinetic-pharmacodynamic 
relationship for MPA are mandatory for the optimal dosing of this drug in 
immunosuppressive therapy following organ transplantation [39]. Since MPA inhibits 
IMPDH, pharmacodynamic monitoring of the degree of inhibition of the enzyme may 
provide a better indicator of immunosuppression than measurement of MPA 
concentrations in plasma. 
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The first IMPDH assays measured the incorporation of radioactivity into purine 
nucleotides following the addition of [14C] hypoxanthine to cell suspensions and 
extracts [75]. Other methods based on [14C] - and [3H]-labeling were used, but lately, 
methods without radioisotopes have been introduced. These are based on incubation 
of cell lysate supplemented with IMP and NAD+ and subsequent liquid 
chromatographic analysis of XMP or xanthine in order to express the IMPDH activity 
[29, 30, 33, 76]. Table 4.2 shows all the factors affecting the IMPDH activity. 
 
Table 4.2  Factor affecting the IMPDH activity in vitro   
Factors IMPDH activity References 
Increase concentration of MPA Decrease [60, 74] 
Increase concentration of MPAG Decrease [60] 
Increase WBC concentration Increase [74] 
Longer storage time Decrease [74] 
Increase protein concentration Increase [29] 
Increase temperature Increase [29] 
Increase incubation time Increase [29, 60] 
Increase IMP concentration Increase [60] 
Increase NAD concentration Increase [60] 
Increase cell washing steps Increase [33] 
 
4.2.3.1 Chemicals and reagents 
 
Inosine monophosphate dehydrogenase Type II (IMPDH II), xanthosine 5’ 
monophosphate (XMP), inosine 5’ monophosphate (IMP) and nicotinamide adenine 
dinucleotide (NAD+) were purchased from Sigma (St. Louis, MO, USA). All other 
reagents were standard high-performance liquid chromatography (HPLC) or 
analytical grade. Lymphocytes were separated from the whole blood sample collected 
from the stable renal transplant patients. 
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4.2.3.2 Study subjects 
 
The same patients of study population for the conventional study (see Section 4.1.1.2) 
were included in this study. For these patients, among six adult renal allograft 
recipients transplanted 7-93 months ago who have participated in the different dose 
interval (12, 24 or 48h) measurement of PK profile, only three patients were included 
in this study of IMPDH activity because of technical difficulties in separation of 
lymphocytes and cells count was not enough to use.  
 
In order to obtain an estimate of the pretreatment (absence of MPA) IMPDH enzyme 
activity venous blood was also collected from the patients (n=4) who were not on 
MMF (1 M, age 42 and other race; 3 F, age 45-49 and all Chinese). 
 
4.2.3.3 Determination of IMPDH enzyme activity in patients’ lymphocytes 
 
An isocratic ion-pair reversed phase high-performance liquid chromatographic 
method was used to determine IMPDH enzyme activity in stable renal transplant 
patients’ lymphocytes as described in Section 3.3. Refer to Section 3.4 for step by 
step lymphocytes sample preparation. 
 
4.3 Data Analysis 
 
The following pharmacokinetic data for total and free MPA and MPAG were 
determined: predose concentration (Cpredose) also known as trough plasma level (C0), 
time to reach maximum concentration (Tmax [h]), maximum concentration (Cmax 
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[mg/L]), total clearance (CL) and renal clearance (CLrenal) of MPA and MPAG, 
formation clearance of metabolite (CLformation [L/h]), and AUC from 0 to 12 h, 0 to 24 
h and 0 to 48 h (τ) respectively. Abbreviated modification of diet in renal disease 
(aMDRD) method was used to estimate golmerular filtration rate (GFR) or creatinine 
clearance (CLCr) (Equation 4.1) [77]. 
 
GFR or CLCr=186 x [serum creatinine (mg/dl)]-1.154 x [age]-0.203 x [0.742 if patient is      
female] (Equation 4.1)  
 
The pharmacokinetic parameters of MPA and MPAG were calculated with a non-
compartmental analysis based on individual subject time-concentration profiles. The 
trough concentration (C0), maximum concentration (Cmax) and time to reach 
maximum concentration (Tmax) of MPA and MPAG were read directly from the 
concentration-time plots. Full AUC 0-τ was determined according to linear 
trapezoidal rule which were performed with software package WinNonLin program 
(version 5.0.1, pharsight, Mountain View, CA, USA).  
 
The dosing rate was calculated by dividing MPA equivalent dose by dosing interval. 
 
The percentage values of unbound (free) MPA and MPAG (%fu) in plasma were 
calculated by dividing unbound concentration of MPA or MPAG in ultrafiltrate  by 
total plasma concentration of MPA and MPAG (×100%) [78].   
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An estimate of steady-state oral total body clearance of MPA and MPAG, total body 
clearance/F (CLss/F) where F is the fraction of dose absorbed or oral bioavailability, 
was obtained from the calculated dose-interval AUC and MMF dose: [79]. 
 
  = τ-0AUCMPA total
dose) equivalent(MPA  dose MMF)MPA(
F
CLss       (Equation 4.2) 
 
 = τ-0AUCMPAG total
dose) equivalent(MPAG  dose MMF)MPAG(
F
CLss        (Equation 4.3) 
 
 The total amount of MPA and MPAG excreted in the urine during 12, 24 or 48 hr (τ) 
was determined by multiplication of MPA and MPAG concentration in pooled urine 
collected over respective dosing interval by the total urinary volume collected. Renal 
clearance (CLrenal) of MPA and MPAG was calculated by dividing the amount of 
MPA and MPAG excreted in urine over a τ period by the MPA and MPAG plasma 
AUC0- τ  as follows: 
MPA amount excreted0- τ
CLrenal (MPA)= MPA AUC0- τ  
  (Equation 4.4) 
                                                                                    
  (Equation 4.5) MPAG amount excreted0- τ




The formation clearance CLformation of metabolite MPAG was calculated by the 
following equation: 
 
   (Equation 4.6) 
 





To assess the underlying mechanism of renal excretion of MPA and MPAG the 
following clearance ratio was computed.  (Equation 4.7): 
 




(Equation 4.7)     
 
The underlying process of renal excretion is the renal filtration only if CLR/F is equal 
to 1; signifies its net active renal secretion if greater than 1 and its net renal 
reabsorption if less than 1. 
 
For the pharmacodynamic, the inhibitory effect of MPA on IMPDH activity was 
calculated using the general formula (Equation 4.8) [80].  
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Statistical data analyses were performed using SPSS 12.0 (SPSS Inc., USA).To assess 
the relationship between unbound fraction and plasma concentration of MPA (or 








4.4.1 Pharmacokinetic study 
 
A pharmacokinetic study  within dosing intervals of free and total MPA and MPAG, 
obtained from six renal transplant patients who received chronic oral dosing of MMF 
(750, 500 and 250 mg b.d., 250 mg e.o.d. and 250 mg o.m.). A total of 6 
concentration-time data points for free and total MPA and MPAG obtained from each 
of 6 patients who had been on MMF for more than 3 months were analyzed. Figure 
4.1 shows the PK profiles of total and free MPA and MPAG concentration, after oral 
MMF administration, characteristically with a rapid increase in total and free MPA 
concentration during the absorption phase, followed by a rapid distribution and slow 
elimination phase. MPA reached the first peak concentration around 0.8 hour and 








Figure 4.1 (A) Characteristic pharmacokinetic and pharmacodynamic profiles of MPA and 
MPAG in patients for conventional study following chronic oral dosing of MMF for more than 3 
months during interval (0-12, 24 or 48 h) (B) Characteristic total and free concentration-time 
profile of MPA and MPAG in patients for conventional study following chronic oral dosing of 






Figure 4.2 (A) Characteristic pharmacokinetic and pharmacodynamic profiles of MPA and 
MPAG in patients for conventional study following chronic oral dosing of MMF for more than 3 
months during interval (0-12, 24 or 48 h) (Semi-log scale) (B) Characteristic total and free 
concentration-time profile of MPA and MPAG in patients for conventional study following 
chronic oral dosing of MMF for more than 3 months during interval (0-12, 24 or 48 h) (PD data 




All the pharmacokinetic parameters estimated for both total and free MPA and 
MPAG, and the pharmacodynamic parameters of patients with different dose and 
dosing intervals are listed in Table 4.3. 
 
The AUC values ranged from 26.21 to 85.73 mg/h/L (46.81±21.44 mg/h/L) for total 
MPA and from 374.60 to 3047.21 mg/h/L (1001.7±1012.67 mg/h/L) for total MPAG. 
The mean free fraction of MPA, determined by the ratio of its free to total AUC, was 
0.64±0.12%, while that of MPAG was 18.1±3.7%. Table 4.4 depicts all the 
pharmacokinetic and pharmacodynamic parameters standardized with dosing rate 

















Table 4.3 Pharmacokinetic  and Pharmacodynamic parameters at steady state in RTxRs following 
chronic oral dosing of MMF for more than 3 months  
Parameters LCLG TCKO LWH CSLA GTH VS Mean±SD CV (%) 
PK parameters         
Plasma data         
MPA         
total MPA C0 (mg/L) 1.11 0.57 0.88 5.76 3.17 3.04 2.42±1.98 81.82 
total MPA Cmax (mg/L) 4.85 6.98 6.71 23.01 8.02 16.95 11.09±7.22 65.10 
total MPA Tmax (h) 0.39 0.32 1.32 0.62 1.52 0.6 0.795±0.5 62.89 
total MPA AUCss (mg.h/L) 51.47 28.76 26.21 85.73 44.69 43.97 46.81±21.44 45.80 
free MPA C0 (mg/L) 0.006 0.004 0.006 0.04 0.017 0.014 0.015±0.014 93.33 
free MPA Cmax (mg/L) 0.03 0.038 0.04 0.237 0.056 0.09 0.082±0.079 96.34 
free MPA Tmax (h) 0.39 0.32 1.32 0.62 1.52 0.6 0.795±0.5 62.89 













0.56   
MPA CL/F 3.59 6.42 7.05 6.47 8.27 4.2 5.99±1.77 29.54 
         
MPAG         
total MPAG C0 (mg/L) 7.6 7.86 19 202.15 52.91 14.79 50.72±76.06 149.96 
total MPAG Cmax (mg/L) 20.16 24.34 39.11 302.65 80.84 44.51 85.27±108.64 127.41 
total MPAG Tmax (h) 1.06 1.01 1.32 2.57 2.03 2.03 1.67±0.61 36.53 
total MPAG AUCss (mg.h/L) 631.37 479.15 708.26 3047.21 769.62 374.6 1001.7±1012.67 101.0 
free MPAG C0 (mg/L) 1.55 0.89 3.87 45.77 11.43 3.61 11.19±17.35 155.05 
free MPAG Cmax (mg/L) 3.05 3.34 7.21 78.9 15.98 8.78 19.54±29.46 150.77 
free MPAG Tmax (h) 0.39 1.32 2.05 1.48 2.03 1.57 1.47±0.61 41.5 













24.41   
MPAG CL/F 0.46 0.6 0.41 0.28 0.75 0.77 0.54±0.2 35.82 
         
Ratio of  total AUC 
(MPAG/MPA) 12.27 16.66 27.02 35.54 17.22 8.52 19.54±9.99 51.13 
Ratio of  free AUC 
(MPAG/MPA) 271.15 348.87 638.58 983.23 668.95 366.7 546.25±268.85 49.22 
         
Urine data         
MPA  amount excreted (mg) 1.32 8.73 19.11 7.96 2.8 2.84 7.13±6.6 92.57 
MPAG amount excreted 
(mg) 92.31 35.8 226.62 403.04 566.18 262.63 264.43±196.77 74.41 
         
Combined plasma and 
urine data         
MPA CLrenal (L/h) 0.026 0.304 0.729 0.093 0.063 0.065 0.213±0.271 127.23 
MPAG CLrenal (L/h) 0.146 0.075 0.32 0.132 0.736 0.701 0.352±0.3 85.23 
CLformation (L/h) 1.79 1.25 8.65 4.7 12.67 5.97 5.84±4.32 73.97 
         
PD parameters         
Predose IMPDH activity 
(nmol/h/mg protein) 29.32 41.17 42.01 NA NA NA 37.5±7.1 18.93 
Minimal IMPDH activity 
(nmol/h/mg protein) 6.71 15.9 19.78 NA NA NA 14.13±6.71 47.49 
% inhibition at Cmin,ss 32.02 4.54 2.59 NA NA NA 13.05±16.45 126.05 
% inhibition at Cmax,ss 84.44 63.13 54.14 NA NA NA 67.24±15.56 23.14 
Abbreviation: RTxR=Renal transplant recipient; MPA=mycophenolic acid; MPAG=mycophenolic acid -phenyl 
glucuronide; C0=trough concentration; Cmax=maximum concentration; Tmax=time to reach Cmax; AUC0-τ=area under the 
concentration-time curve from 0 to τ h; fu=free fraction; CLrenal=renal clearance; CLformation=formation clearance; 




Table 4.4 Normalized PK and PD parameters in patients for the conventional study following chronic oral dosing 
of MMF for more than 3 months 
Parameters LCLG TCKO LWH CSLA GTH VS Mean±SD CV (%) 
PK parameters         
Plasma data         
MPA         
atotal MPA C0 (mg/L) 0.00437 0.00238 0.00201 0.00289 0.00178 0.0038 0.16±0.07 34.22 
atotal MPA Cmax (mg/L) 0.191 0.035 0.015 0.012 0.005 0.021 0.018±0.01 57.55 
atotal MPA AUCss 
(mg.h/L) 0.203 0.143 0.06 0.043 0.025 0.056 0.088±0.069 78.56* 
afree MPA C0 (mg/L) 0.000023 0.000019 0.000014 0.00002 0.00001 0.000018 0.000017±0.000005 29.02 
afree MPA Cmax (mg/L) 0.00012 0.00019 0.000091 0.00012 0.000031 0.00011 0.00011±0.000051 46.01 
afree MPA AUCss 
(mg.h/L) 0.0013 0.001 0.00043 0.00035 0.00013 0.0003 0.0006±0.00045 78.4* 
bMPA CL/F 0.054 0.123 0.124 0.15 0.143 0.082 0.113±0.037 32.87 
         
MPAG         
atotal MPAG C0 (mg/L) 0.019 0.025 0.028 0.065 0.019 0.012 0.028±0.019 67.56 
atotal MPAG Cmax 
(mg/L) 0.051 0.078 0.057 0.097 0.029 0.036 0.058±0.026 44.21 
atotal MPAG AUCss 
(mg.h/L) 1.60 1.53 1.04 0.98 0.28 0.30 0.95±0.57 59.85 
afree MPAG C0 (mg/L) 0.004 0.003 0.006 0.015 0.004 0.003 0.0057±0.0045 79.64 
afree MPAG Cmax 
(mg/L) 0.008 0.011 0.011 0.03 0.006 0.007 0.011±0.007 64.43 
afree MPAG AUCss 
(mg.h/L) 0.220 0.216 0.174 0.218 0.057 0.063 0.158±0.078 49.1 
bMPAG CL/F 0.0069 0.0115 0.0071 0.0066 0.0129 0.015 0.009±0.0036 36.11 
         
Urine data         
aMPA  amount 
excreted (mg) 0.0051 0.0433 0.0436 0.004 0.0015 0.0036 0.0169±0.021 122.18* 
aMPAG amount 
excreted (mg) 0.234 0.114 0.332 0.130 0.204 0.214 0.205±0.08 38.4 
         
Combined plasma and 
urine data         
bMPA Clrenal (L/h) 0.0004 0.0058 0.013 0.0022 0.0011 0.0013 0.039±0.0048 121.28 
bMPAG Clrenal 0.0022 0.0014 0.0056 0.0031 0.013 0.014 0.0064±0.0054 83.96 
bClformation (L/h) 0.027 0.024 0.151 0.109 0.219 0.116 0.108±0.075 69.27 
         




 (nmol/h/mg protein) 




0.026 0.079 0.045 NA NA NA 0.05±0.027 53.13 
a% inhibition at Cmin,ss 0.126 0.023 0.006 NA NA NA 0.052±0.07 126.33 
a% inhibition at Cmax,ss 0.332 0.313 0.123 NA NA NA 0.256±0.12 45.09* 
Abbreviation: MPA=mycophenolic acid; MPAG=mycophenolic acid -phenyl glucuronide; C0=trough concentration; Cmax=maximum 
concentration; AUCss=area under the concentration-time curve from 0 to τ h; Clrenal=renal clearance; Clformation=formation clearance; 
CL/F=apparent clearance; IMPDH=Inosine monophosphate dehydrogenase; NA=not available 
a adjusted with dosing rate/body weight (mg/hr/kg) 
    
b adjusted with body weight (kg) 
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The inter-individual variability (percent coefficient of variation CV %) of dosing rate 
and body weight-normalized (mg/h/kg) or body weight (kg) adjusted values of MPA 
and MPAG pharmacokinetic and pharmacodynamic parameters are much lower 
compared to those of non-adjusted values except a few cases in which no such an 
improvement was seen with total MPA AUC, free MPA AUC, MPA amount excreted 
in urine, percent inhibition of MPA at Cmax, ss. (See Table 4.3 and 4.4) 
 
There are some correlation between MPA concentration and MPA free fraction 
(r2=0.2512, p<0.01), MPAG concentration and MPAG free fraction (r2=0.3416, 
p<0.01), MPA concentration and MPAG free fraction (r2=0.1886, p<0.01) and MPAG 
concentration and MPA free fraction (r2=0.2246, p<0.01). However, MPA free 
fraction and MPAG free fraction has no statistically significant relationship. Such 





























Figure 4.3 Scatter plot of free fraction of MPA versus MPA concentration  
 
 
























Figure 4.4 Scatter plot of free fraction of MPAG versus MPA concentration 
 
 

























Figure 4.5 Scatter plot of free fraction of MPAG versus MPAG concentration  
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Figure 4.6 Scatter plot of free fraction of MPA versus MPAG concentration 
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Figure 4.7 Scatter plot of free fraction of MPAG versus free fraction of MPA 
 
 
Table 4.5 summarizes the mechanism of renal excretion (CLR/G) of MPA and its major 
metabolite MPAG. There was net active secretion of MPA observed in all 6 patients. 
However, the net renal reabsorption of MPAG was found only in three of six patients 





Table 4.5 Mechanism of renal excretion of MPA and MPAG in RTxR for conventional study  
MPA  MPAG 
Patient Sampling time (h) CLR/G
Mechanism of renal 
excretion  CLR/G
Mechanism of renal 
excretion 
LCLG 0 2.72 net active secretion  0.428 net reabsorption 
 0.5 2.51 net active secretion  0.518 net reabsorption 
 1 3.11 net active secretion  0.706 net reabsorption 
 6 2.33 net active secretion  0.784 net reabsorption 
 48 2.72 net active secretion  0.428 net reabsorption 
       
TCKO 0 28.6 net active secretion  0.484 net reabsorption 
 0.5 41.09 net active secretion  0.496 net reabsorption 
 1 25.22 net active secretion  0.413 net reabsorption 
 1.5 22.82 net active secretion  0.387 net reabsorption 
 2 23.91 net active secretion  0.436 net reabsorption 
 6 44.25 net active secretion  0.326 net reabsorption 
 48 28.6 net active secretion  0.484 net reabsorption 
       
LWH 0 92.51 net active secretion  1.32 net active secretion 
 0.5 87.7 net active secretion  1.01 net active secretion 
 1 92.07 net active secretion  1.9 net active secretion 
 1.5 102.82 net active secretion  1.7 net active secretion 
 2 70.27 net active secretion  1.44 net active secretion 
 4 82.2 net active secretion  1.82 net active secretion 
 24 92.51 net active secretion  1.32 net active secretion 
       
CSLA 0 11.17 net active secretion  0.489 net reabsorption 
 0.5 7.55 net active secretion  0.442 net reabsorption 
 1 7.32 net active secretion  0.39 net reabsorption 
 1.5 7.52 net active secretion  0.4 net reabsorption 
 2 9.95 net active secretion  0.501 net reabsorption 
 4 14.22 net active secretion  0.549 net reabsorption 
 12 11.17 net active secretion  0.489 net reabsorption 
       
GTH 0 6.84 net active secretion  2 net active secretion 
 0.5 8.65 net active secretion  2.28 net active secretion 
 1 7.42 net active secretion  2.09 net active secretion 
 1.5 5.26 net active secretion  1.85 net active secretion 
 2 5.66 net active secretion  2.18 net active secretion 
 4 11.04 net active secretion  2.07 net active secretion 
 12 6.84 net active secretion  2 net active secretion 
       
VS 0 5.1 net active secretion  1.05 net active secretion 
 0.5 4.45 net active secretion  1.44 net active secretion 
 1 4.24 net active secretion  1.23 net active secretion 
 1.5 4.59 net active secretion  1.67 net active secretion 
 2 4.61 net active secretion  1.44 net active secretion 
 4 5.92 net active secretion  1.19 net active secretion 
 12 5.1 net active secretion  1.05 net active secretion 
CLR/G =CLR/(fu*GFR)     
CLR/G =1 filtration only     
CLR/G >1 net active secretion     







4.4.2 Pharmacodynamic study 
 
With regard to the effect of MPA concentrations on IMPDH activity, for all the 
patients in our study an inverse relationship between MPA levels and IMPDH activity 
was observed. All the PD profiles are presented in Figure 4.1. 
 
Pretreatment IMPDH activity (in the absence of MPA) from renal transplant patients 
(n=4, 3 Chinese and 1 other race), receiving no MMF, was found to be 43.13±6.81 
nmol/h/mg protein, ranging from 36.92 to 52.84 nmol/h/mg protein (CV=15.79%). In 
the present study, there was a considerable variability of predose IMPDH activity 
from 3 stable renal transplant recipients under MMF therapy ranging from 29.32 to 
42.01 nmol/h/mg protein (37.5±7.1 nmol/h/mg protein), suggesting that the minimum 
inhibition of MPA at its trough level (Cmin,ss) was 13.05±16.45%, ranging from 2.6 to 
32.02%. In parallel to MPA peak concentrations (Cmax, ss), the maximal inhibition 
occurred approximately 1 hour after dosing (Refer to Table 4.3), with the mean value 
of 67.24±15.56% ranging from 54.14 to 84.44%. The minimum IMPDH activity at 
Cmax, ss was nearly 2.5-fold lower than that of predose activity at Cmin, ss depending on 
the MMF dose and MPA concentration. 
 
On the other hand, as long as the MPA plasma concentration decreases to its trough 
level at the end of the dosing interval prior to its next dose, IMPDH activity is being 
restored to its predose C0 level. Complete inhibition of IMPDH was not observed at 
the highest concentration of MPA investigated in this study. 
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The PK and PD data obtained from the patients of the conventional study were used 
for the model fitting to characterize the PK-PD relationship of both the total and free 
concentration of MPA with its IMPDH activity. However, out of six patients, only 
three patients were included in this study as there was not enough data for the PD 
measurement (IMPDH enzyme activity) because of samples with insufficient MNC 




Compared to the recommended dose of 1 g twice daily (dosing rate 61.58 mg/hr) 
administered in the Western population, the dose administered in the local population 
is comparatively lower (dosing rate 17.96 ±17.1 mg/hr), as observed in the 6 study 
subjects (Table 4.1). 
 
It was found that the pattern of total and free MPA and MPAG plasma concentration-
time profiles in the patients taking lower doses of MMF was consistent with previous 
studies performed in Caucasian taking MMF 1 g b.d., except that the dosing rate and 
body weight-normalized exposure of total MPA AUC (0.088±0.069, range,0.025-
0.203) was higher in the current study that in those of Chinese (0.014±0.003, range 
0.003-0.02, n=31), and Korean (0.0069±0.002, n=10) who receive concomitant CsA  
and steroid therapy[68, 71, 81, 82]. The pharmacokinetic profiles of MPA in our 
patients are characterized by an early and sharp increase of MPA concentration. A 
rapid absorption and rapid conversion of MMF to MPA, followed by rapid 
distribution and metabolism of MPA, consistent with the results reported by Weber et 
al. [45] 
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Similarly, dosing rate and body weight normalized value of free MPA AUC in our 
study (0.0006±0.00045 mg/h/kg, range 0.00013-0.0013) was higher than those of 
Chinese who receive concomitant CsA and steroid (0.0002±0.0001 mg/h/kg, ranged 
from 0.00006-0.0005) [71]. 
 
The same dose of MMF (1g twice daily) would lead to approximately two times 
increase in the AUC of MPA in patients receiving sirolimus compared to cyclosporine 
(81±39 mg.h/L and 43±11 mg.h/L respectively) [83]. All the patients for conventional 
study in this study received reduced dose of MMF with sirolimus (see table 4.1) 
because patients taking MMF and sirolimus experience a higher exposure to MPA and 
a lower exposure to MPAG. Mean total AUC ratio of MPAG to MPA 19.54±9.99 
(range 8.52-35.54) is lower in MMF and sirolimus receiving patients than those being 
treated with MMF and cyclosporine (mean AUC ratio of MPAG to MPA 35.3 (range 
33.23-36.76)) [52]. This interaction is probably caused by inhibition of mycophenolic 
acid glucuronidation or glycosylation. 
 
All six patients in the present study had a co-administration of MMF and SRL. In the 
study of Vu et al. [84], the combined use of MMF and SRL showed a very strong 
synergistic interaction in the prevention of heart, pancreases and kidney allograft 
rejection, and reversal ongoing heart allograft rejection in the rats [3]. Although SRL 
and MMF can be administered in this setting without exacerbating the impaired renal 




In the study of Shaw et al., which included renal and heart transplant patients, the 
incidence of acute rejection is significantly related to total MPA AUC [41]. As MMF 
absorption and MPA pharmacokinetics are diverse among individuals when given at 
the recommended dosage (1 g twice daily), it is important to monitor total MPA AUC 
in a clinical setting. Shaw et al. reported that the target range of the total MPA AUCss 
is 30-60 mg.h/L [85]. In this study, almost all the patients were within this range 
except one patient who had a higher value of 85.73 mg.h/L. However, MPA AUC 
range in our study (26.21-85.73 mg.h/L) is quite close to Chen et. al. study (19.99-
98.73 mg.h/L) [67]. In acute renal transplant patients, a greater than 10-fold range 
(3.7-44.4 mg.h/L) in MPA AUC has been observed in individuals receiving the same 
dose (1 g twice daily) in Atcheson et. al. study [70]. Moreover, a range of intra-
individual variability for MPA AUC of 13-80% (% CV) has been described [86]. 
 
 A large variability in MPA pharmacokinetics found in Chinese liver transplant 
recipients suggests that MPA concentration should be monitored routinely for the 
individualization of MMF administration. It has been suggested that MPA C0 could be 
used as the indicator for MMF dose adjustment. Therapeutic range of MPA C0 is from 
1 to 3.5 mg/L based on liver transplant patients’ data [67]. In our study, all the 
individual patients’ MPA C0 was 2.42 mg/L were within the therapeutic range. 
 
In the present study, there was no blood sampling done between 6 and 12 h after 
MMF administration, thereby possibly missing part of the second plasma peak of 
MPA which sometimes shows and has been attributed to the enterohepetic cycle. 
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Regarding MPAG, the results showed that it had a very high plasma concentration 
compared to MPA. It has been reported that the primary metabolite MPAG present in 
human plasma is approximately 20 to 100 times the concentration of MPA and in 
renal impaired patients, the values are even 100-fold higher [87].  
 
Another finding in the current study is that predose MPAG total concentration (C0) 
7.6–202.15 mg/L and free MPAG concentration of 0.89–45.77 mg/L in stable RTxRs 
treated with MMF and SRL  in current study were lower than those in others reported 
values in RTxRs treated with MMF and CsA (36–199 mg/L and 8-55 mg/L). The 
range of MPAG free fraction value measured in the present study (11.17-27.69%) is 
higher than previously reported in RTxRs treated with MMF and CsA (17-54%) [70]. 
The mean free fraction of MPA and MPAG measured was 0.654±0.18 % and 
19.18±4.7 % respectively and it changes with time. In the present investigation, the 
protein binding of MPA was approximately 99% for MPA and 80% for MPAG. 
Because MPA is extensively bound to serum albumin and only the free concentration 
of MPA in plasma is  pharmacologically active, we observed that there was some 
change in the free fraction of MPA throughout the dosing interval and wide variation 
as indicated by the large data range was observed (0.333-1.062%). Cho et al. [82] 
reported that the free fraction of MPA in Korean patients (1.6±0.2%) does not seem to 
be different from reported data by Weber et al. (median 1,65%, range, 0.4-13.8%) 
[45].  
 
In agreement Jiao et al. study [71], it was also noted that there was a large inter-
subject variability of PK parameters was observed for free MPA and MPAG than total 
MPA and MPAG  A larger variation in free MPA AUC (CV 61.29 %) and free 
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MPAG AUC (CV 119.82%) was observed compared to total MPA AUC (CV 45.8%) 
and total MPAG (CV 10.10%).  
 
Jiao et al. [71] reported the AUC0-12 value of 656±148 (375-824) mg.h/L (mean 
normalized with dosing rate and body weight value 0.12±0.03 (0.06-0.15) mg.h/L) for 
total MPAG after transplantation in Chinese RTxR. Those results are lower than the 
normalized value 0.95±0.57 in the current study. To our knowledge, there have been 
few publications on the AUC of the free MPAG. In Jiao et al. study [71] normalized 
free MPAG AUC 0-12h was 0.04±0.01 mg.h/L (range: 0.02-0.06 mg.h/L) in Chinese 
RTxR. Compared to 0.158±0.078 mg.h/L (range: 0.057-0.22 mg.h/L) in our 
investigation, the exposure to free MPAG was also higher than that of Jiao’s finding 
and the range was wider compared to those previous study. As MPAG is mainly 
cleared via the kidney, poor renal function can reduce renal excretion of MPAG and 
increase MPAG accumulation in the body. 
 
We have also observed that the mean oral clearance of MPA (CL/F) was 5.99±1.77 
L/h which was much lower than others findings (15.67±11.19 L/h and 42.67±9.97 
L/h) [68, 82] and which appears to decrease in proportion to decreased free fraction of 
MPA. It is due to the fact that patients taking MMF and SRL experience a higher 
exposure to MPA and a lower exposure to MPAG than those being treated with MMF 
and CsA [52]. Also, it is demonstrated that lower MPAG concentration cannot 
compete with in displacing MPA from albumin binding site which in terms leads to 
decrease MPA free fraction and thus less MPA available for metabolization and 
subsequent elimination. This finally leads to decrease MPA clearance [79]. 
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In the kidneys, drugs usually undergo filtration, active secretion and passive 
reabsorption, but to various extent. In the current study, a net active secretion of MPA 
was observed in all the six patients studied as the MPA is the weak acidic compound. 
Drug molecules are transferred to the tubular lumen by two independent and relatively 
non-selective carrier systems. One of these carriers transports acidic drugs. Therefore, 
net active tubular secretion is potentially the most effective mechanism of renal drug 
elimination. That carrier-mediated transport can achieve maximal drug clearance even 
for the high plasma protein binding drug like MPA [88]. About 95% of MPA in the 
body is eliminated as MPAG by transepithelial secretion. However, among the six 
patients tested, three patients showed net active secretion but the other three showed 
net reabsorption for MPAG. The latter three patients were taking diuretic frusemide 
concomitantly. Frusemide may inhibit secretion of MPAG in renal tubules [88] and 
that will explain why the three patients taking MMF with frusemide showed net 
reabsorption of MPAG. 
 
In the present study, the biological response to MMF was investigated directly by 
measuring IMPDH activity. Only limited data are available about IMPDH activity in 
MMF treated renal transplant patients. Most of the investigations are limited due to 
the technical difficulties in lymphocytes isolation and tedious assay systems used so 
far, that did not allow measurement of IMPDH activity in lymphocytes in larger 
sample size [33]. 
 
Predosing IMPDH activity of MPA, prior to its next dose, was inversely correlated 
with MPA trough concentration and maximal inhibition coincidented with maximal 
MPA concentration. Budde et al. showed that IMPDH activity dramatically decreased 
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by 1 hour after MMF intake, remained suppressed after 4 hours, but then returned to 
within the normal range (9.4-15.2 nmol/h/mg protein) after 11 hours [34]. As shown 
in Figure 4.1 (A), it was consistently observed that IMPDH decreased significantly by 
1 hour after MMF ingestion then increased. Just before next dose, it had returned to 
the normal range (29.32-42.01 nmol/h/mg protein).  
 
All patients receiving MMF for more than 3 months had a rapid and significant 
decline of IMPDH activity in lymphocytes. Sanquer et al. [89] described 40-90% 
inhibition and Langman et al. [90] showed 40% inhibition of IMPDH activity during 
peak concentrations. Similarly, Glander et al. [33] found strong inhibition of IMPDH 
activity in lymphocytes ranging from 47-95%. In contrast to these findings, Storck et 
al. [31] observed a small increase of IMPDH activity in lymphocytes after intake of 
the drug. This could be due to the fact that MPA had been washed out during 
preparation of cell lysates. Abbreviation of washing procedure resulted in a decrease 
of IMPDH activity and an additional washing step caused an increase of IMPDH 
activity. In this study, washing steps were abbreviated to avoid washing out of MPA 
from MNC lysates. 
 
A trend to an inverse relationship was noted between IMPDH activity and both total 
and free MPA concentrations. However, in agreement with other in vitro studies, 
there is a stronger relationship between IMPDH activity and the free rather than the 
total MPA concentration. It clearly indicates that free concentration of MPA reflects 




Due to small numbers of patients, differences in the study design, it is too preliminary 






















































Pharmacokinetics and pharmacodynamics explain the interaction of a drug to a 
biological environment. Mathematical model of the system is often chosen and then 
the data is used to define the values for unknown model parameters. The model 
parameters function as measures for comparison of results both within and between 
experiments and these are determined from a fit of the model to the observed data. A 
variety of methods are used and one approach is the application of areas under the 
concentration-time curve, often denoted as noncompartmental analysis or NCA. 
Another approach deals with different forms of regression models and curve fitting 
techniques of which compartmental analysis is one of the most popular. A model 
should also be an easy and flexible way to predict data, for example, predict the time 
course after multiple dosing based on single dose data. The model can also be used to 
explain unclear observations [92].  
 
Oral drug plasma concentration-time data can be analyzed using conventional 
compartment models with first order input. The main objective of this study is to 
select a suitable PK model and PD model to describe the PK concentration-time 
profile and PD profile of MPA and to estimate the PK and PD parameters of MPA in 
renal transplant patients on oral MMF. 
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5.2 Pharmacokinetic modeling 
 
5.2.1 Patients and methods  
 
In order to fit the total and free MPA plasma concentration-time curve in stable RTxR 
following chronic oral dosing of MMF, two different pharmacokinetic models, 
namely one compartmental model and two compartmental model,  were used. PK 
modeling was performed using WinNonLin Version 5.0.1 computer program 
(Scientific Consulting Inc., Lexington, KY, USA), an iterative curve-fitting program 
based on nonlinear regression analysis. 
 
MMF doses of all the patients were converted to the equivalent MPA content by 








MPA ==   (Equation 5.1) 
 
where MWMPA is molecular weight of MPA and MWMMF molecular weight of MMF. 
 
5.2.1.1 One compartment model 
 
In one compartment model with first-order elimination that is the simplest disposition 
model (Figure 5.1), the administration of drugs by oral route introduces an absorption 
step with first-order absorption and lag time in absorption. The change in body drug 
content or plasma drug concentration is now more complex, since the rate of change 
of drug is a function of both the absorption rate and elimination rate [94]. K01 is the 
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first-order fractional absorption rate constant per unit time and K10 is the fractional 
elimination rate constant from central compartment per unit time.  
 
WinNonLin compiled model: 




EXP(-K01*(T-Tlag))/(1-EXP(-K01*ι)] (Equation 5.2) 
Figure 5.1 Schematic presentation of the one-compartment model with first order elimination 
 
 
 5.2.1.2 Two compartment model 
 
Two-compartment model is more complex than the one-compartment model, as it 
introduced additional compartments for distribution and re-distribution of the drug 
between a central-(blood and rapidly equilibrated organs) and a peripheral 
compartment (more slowly equilibrating tissues, which may either be poorly perfused 
or surrounded by protective membranes). This model requires a longer time in order 
to achieve total distribution equilibrium between blood and tissues [94]. K12 is the 
fractional rate constant from central compartment to peripheral compartment per unit 
time. K21 is the fractional rate constant from peripheral compartment to central 
compartment per unit time. The model is depicted schematically in Figure 5.2. All the 
output charts are presented in Figure 5.7 and 5.8 respectively.  
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The secondary parameter values for the 2 compartment model (first order absorption 
and elimination with lag time) were calculated from the following equations: 
 
CL=K10*V1   (Equation 5.3) 
 Q=K12*V1=K21*V2  (Equation 5.4) 
 V2= (K12/K21)*V1  (Equation 5.5) 
 α+β=K12+K21+K10  (Equation 5.6) 
 α*β=K21*K10  (Equation 5.7) 
 
WinNonLin compiled model: 




































Tlag)) (Equation 5.8) 





5.2.2 Model discrimination 
 
It is important to be careful when interpreting the results of a fit from these two values 
the Akaike Information Criterion (AIC) and the Schwarz Criterion (SC) or the F-test. 
The goodness-of-fit cannot be judged without a battery of statistical tools. When 
comparing more than one model, the most appropriate model is the one with the 
smallest value of AIC and SC. SC is used similarly as the AIC. 
 
To know the model discrimination between one compartment and two compartment 
models, the goodness-of-fit criteria, including weighted residual sum of squares 
(WRSS), AIC and the coefficient of determination (r2) between predicted and 
observed data were applied. AIC value was calculated from equation 5.9,  
 
AIC=NobsLn(WRSS)+2Npar  (Equation 5.9) 
 
where, Nobs is the number of observations, and Npar is the number of parameters. The 
larger value of r2 and smaller value of AIC and WRSS is the better and more suitable 
model. 
 
Furthermore, the F-test was performed to assess whether the full model (e.g., two-
compartment model) was statistically superior to the reduced model (e.g., one-
compartment model). The F-statistic was calculated according the following equation: 
                                           |WRSS1-WRSS2|  
                                                  |df1-df2|                    (Equation 
5.10) F =
                                                  WRSS2












are the degrees of freedom for the reduced and full models. Degree of 











= column and df
2 
= row), it means that the full model is statistically 
superior to the reduced model.  
 
5.3 Pharmacodynamic modeling 
 
Pharmacodynamic can be defined as the study of the biochemical and physiological 
effects of drugs and their mechanisms of action. Pharmacodynamic models describing 
the relationship between the concentration of drug in blood or plasma and drug 
receptors provide clinically useful information regarding the baseline and maximal 
effects (sensitivity effect) and the change in the observed effect with time (temporal 
aspects) [95].  
 
When the pharmacological effects are seen immediately and are directly related to the 
drug concentration, a PD model such as a linear model or a sigmoid Emax model is 
applied to characterize the relationship between drug concentration and effect. When 
pharmacologic response takes time for development and the observed response is not 
apparently related to plasma concentrations of the drug, a link model is usually 
applied to relate the PK of the drugs to its PD. 
 
In the present study a different approach was used to relate kinetics to the dynamics 
with link model which is known as indirect pharmacodynamic response model (IPR). 
It is typically based on sound biological principles with prior knowledge about the 
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mechanisms of drug action in that the variables and parameters have a physiological 
meaning and can often be related to in vitro or other physiological data. Therefore, 
this link model (IPR) approach gives us a better understanding of both intra- and 
inter-individual variability in drug response [95].  
 
5.3.1 Patients and methods 
 
Two different indirect pharmacodynamic response (IPR) models as a linked model 
(IPR built-in model and IPR user-defined model) have been used to fit the PD profile 
of MPA (time Vs response). PD modeling was performed using WinNonLin Version 
5.0.1 computer program (Scientific Consulting Inc., Lexington, KY, USA), an 
iterative curve-fitting program based on nonlinear regression analysis. Both IPR 
models treat the pharmacokinetics parameters as fixed and generate concentrations at 
the effect sites to be used by the PD model. 
 
MMF doses of all the patients were converted to the equivalent MPA content by 
multiplying the MMF dose by 0.739 (Equation 5.1) [93] 
 
5.3.1.1 Link indirect pharmacodynamic response built-in model 
 
Sequential approach to PK-PD modeling was used to get PK-PD parameter estimates. 
The estimates of PK parameters were initially obtained from the fitting of plasma 
MPA data of each patient to the PK model.  The subsequent fitting of the observed 
response data to a combined PK-PD model was then performed, by holding an 
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individual patient’s PK parameters as the fixed constants, to get estimates of PD 
parameters for that patient. 
 
In this combined model (see Figure 5.3), the two compartment disposition model with 
first-order absorption (with lag time) and elimination (i.e., PK model 12) was used for 
the pharmacokinetic modeling for both total and free MPA concentrations and the 
simple Emax model (i.e., PD model) was used for the phramacodynamic modeling.  
 
For a combined PK-PD model, the physiological-based indirect model with inhibition 
of production process (Kin) was used as a link model between PK and PD.  
Integration of the link model with the PD model forms the indirect pharmacodynamic 
response (IPR) model as shown in Figure 5.3.   A combined PK-PD model was 
obtained by integrating the IPR model with the PK model, where Kin is the zero- 
order constant for production of response, Kout is the first-order constant for loss of 
response and IC50 is the drug concentration which produces 50% of maximum 
inhibition. 
 





R= (Emax.Cγ)/ (IC50γ+Cγ) 
 












































 (Equation 5.12) 
 
Figure 5.3 Indirect pharmacodynamic response built-in model (Inhibition of input) for both total 
and free MPA and its response in stable renal transplant patients for conventional study 




























Figure 5.4 Observed IMPDH activity time course in a stable renal transplant patient following 






5.4 Results and Discussion 
 
5.4.1 Pharmacokinetic modeling 
 
The plasma concentration-time profiles of both total and free MPA that were fitted 
into one compartment and two compartment models are illustrated individually in 
Figure 5.5 to Figure 5.8. 
 
Visual inspection of the best fitting curve revealed that the two-compartment model 
was better to describe the change of free and total MPA concentration with time than 
the simplest one-compartment model. A summary of goodness-of-fit parameters for 
both total and free MPA such as WSSR, AIC and r2 are presented in Table 5.1 and 
Table 5.2 for one compartment and two-compartment model, respectively. Between 
these two models, the best fit model for each individual patient was selected based on 
goodness-of-fit criteria (WSSR, AIC and r2). Overall, two compartment model gave 
larger r2 and smaller WSSR and AIC values compared to the one compartment model. 
As shown in Table 5.3 and 5.4, the results of the F-test indicated that two-
compartmental model was statistically superior to one compartmental model for most 











































































































Figure 5.5 Plasma concentration time profile of total MPA in patients for conventional study 






































































Figure 5.6 Plasma concentration-time profile of free MPA in patients for conventional study 




































































































Figure 5.7 Plasma concentration-time profile of total MPA in patients for conventional study 














































































Figure 5.8 Plasma concentration-time profile of free MPA in patients for conventional study 
following chronic oral dosing of MMF after fitting in two compartment model 
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Table 5.1 Summary of goodness of fit parameters for total MPA in 2 different model for individual 
patients for conventional study 
WSSR  DF  AIC  R2Subjects 
OMC TCM  OCM TCM  OCM TCM  OCM TCM 
LCLG 2.83377 0.772355  3 1  14.24965 8.45014  0.9749 0.9752 
TCKO 1.4423 3.11573  3 1  10.56367 19.95525  0.9917 0.9576 
LWH 2.92248 0.542574  3 1  15.50702 7.71998  0.9859 0.9917 
CSLA 78.8383 6.5501  3 1  38.57179 25.15636  0.99469 0.9876 
GTH 8.88089 1.30884  3 1  23.28731 13.88398  0.8379 0.9795 
VS 25.6132 1.626  3 1  30.70174 15.40285  0.9775 0.9972 
OCM: One compartment model with lag time (model 4); TCM: Two compartment model with lag time (model 12) 
 
Table 5.2 Summary of goodness of fit parameters for free MPA in 2 different model for individual 
patients for conventional study 
WSSR  DF  AIC  R2Subjects 
OMC TCM  OCM    TCM  OCM TCM  OCM TCM 
LCLG 0.00162 0.000321  3 1  -36.9852 -38.2553  0.8149 0.8818 
TCKO 0.00178 0.0000965  3 1  -36.302 -52.7203  0.9092 0.9382 
LWH 0.00117 0.000597  3 1  -39.2267 -39.964  0.8771 0.7464 
CSLA 0.0384 0.0247  3 1  -14.8181 -13.916  0.8425 0.958 
GTH 0.0131 0.0128  3 1  -22.364 -18.5199  0.5223 0.5495 
VS 0.000621 0.00553  3 1  -43.6857 -24.3806  0.9955 0.9817 
OCM: One compartment model with lag time (model 4); TCM: Two compartment model with lag time (model 12) 
 
Table 5.3 Model discrimination between one compartment and two compartment model for total MPA 
concentration using F-test 
WSSR  Subjects 
OCM TCM  
F-values 
LCLG 2.83377 0.772355  1.3345 
TCKO 1.4423 3.11573  0.26855 
LWH 2.92248 0.542574  2.193163 
CLSA 78.8383 6.5501  5.518099 
GTH 8.88089 1.30884  2.892657 
VS 25.6132 1.626  7.376138 
OCM: one compartment model (model 4); TCM: two compartment model (model 12) 
*F-test, P value <0.05   
 
 
Table 5.4 Model discrimination between one compartment and two compartment model for free MPA 
concentration using F-test 
WSSR  Subjects 
OCM TCM  
F-values 
LCLG 0.00162 0.000321  2.023364 
TCKO 0.00178 0.0000965  8.722798 
LWH 0.00117 0.000597  0.479899 
CSLA 0.0384 0.0247  0.277324 
GTH 0.0131 0.0128  0.011719 
VS 0.000621 0.00553  0.44385 
OCM: one compartment mode (model 4); TCM: two compartment model (model 12) 
*F-test, P value <0.05   
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5.4.2 Pharmacokinetic parameter estimation 
 
After selecting the appropriate model for the MPA PK profile, the plasma drug 
concentration-time profile were analyzed using two-compartmental model with the 
first order absorption and elimination rate constant and lag time. 
 
The initial and bound values of PK parameters for the initial dilution volume of 
distribution [V1_F], absorption rate constant [Ka or K01], time lag in absorption 
[Tlag], fractional rate constant from central compartment to peripheral compartment 
[K12], fractional rate constant from peripheral compartment to central compartment 
[K21] and elimination rate constant [K10], were user-specified and selected prior to 
the initiation of PK modeling.   The estimates of the PK parameters were then 
obtained by the best curve fitting of plasma concentration data of individual patient to 
the two-compartment model. The estimated pharmacokinetic parameters of total and 
free MPA are summarized in Table 5.5 and Table 5.6, respectively. 
 
It was noted that the mean value total AUC (52.68±23 mg.h/L) in our fitting data was 
higher compared to population mean AUC value (33.9±8.95 mg.h/L) in Liang et al. 
study using 2 compartmental model with lag time (Chinese origin, 1g MMF b.d.). 
Mean total CL/F, 5.63±2 L/h was lower during sirolimus co-administration compared 
to other reported CL/F value (range from 14.9 to 34.9 L/h in adults receiving CsA 
therapy and from 11.9 to 25.4 L/h in adults on tacrolimus [96]. However, other 
parameters such as V1, K01, K10, K12, K21 and Q value were quite close to other 
reported values [64, 93, 96-99]. To our knowledge, all of the above PK models were 
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developed solely based on total MPA concentrations and free (unbound) MPA 
concentrations were not measured. 
 
It was also noted that a larger iner-individual variability of PK parameter was 
observed for free MPA than for total MPA after model fitting. The coefficients of 
variation (CV %) of free MPA AUC and CL were 94.8 and 72% respectively, and for 
total MPA, 44 and 39.9 % respectively. 
Table 5.5 Estimated PK parameters (mean±SD) of total MPA in stable renal transplant patients for conventional 






















LCLG 3.19 1.7 0.91 9.99 0.09 0.000001 63.975 2.89 350.41 31.89 
TCKO 13.93 4.19 0.449 1.52 0.0597 0.000001 29.537 6.255 354.52 21.18 
LWH 11.39 2.22 0.643 1.51 0.034 0.95 25.198 7.33 510.2 17.16 
CSLA 3.77 1.028 1.719 4.072 0.032 0.223 85.465 6.485 485.67 15.362 
GTH 30 1.925 0.266 1.196 0.076 0.91 45.98 8.036 474.65 36.101 
VS 4.67 9 0.6 1.7 0.017 0.0065 65.94 2.8 466.99 7.939 
Mean±SD 11.16±10 3.34±2 0.77±0.5 3.33±3 0.052±0.02 0.42±0.4 52.68±23 5.63±2 440.4±69 21.6±10 
CV% 91.6 88.7 67 102.8 55 119.9 44 39.9 15.8 49 
V1_F= initial dilution volume of distribution; K01=absorption rate constant; K10=elimination rate constant; 
K12=fractional rate constant from central compartment to peripheral compartment; K21=fractional rate constant from 
peripheral compartment to central compartment; CL_F=apparent oral clearance; V2_F=apparent volume of the 
peripheral compartment; Q_F=distribution clearance of peripheral compartment; AUC=area under the curve; 
Tlag=lag time in absorption 
 
Table 5.6 Estimated PK parameters (mean±SD) of free MPA in stable renal transplant patients for conventional 






















LCLG 80 25 14 11 7.58 0.09 0.1650 1120 116.09 880 
TCKO 120 1.7 29 19 16 0.02 0.0531 3479 142.5 2280 
LWH 90 0.6 16 15 1.7 0.6 0.1283 1439 794.11 1350 
CSAL 95 2.4 8 7 0.6 0.1 0.7293 760 1108 665 
GTH 80 1.3 30 9 9 0.7 0.1540 2400 80 720 
VS 60 3.3 8 8 0.3 0.06 0.384896 480 1600 480 
Mean±SD 89±21 1.86±1 18.2±10 11.6±5 5.52±6.8 0.296±0.3 0.29±0.2 1711.6±1234 744.9±646 1099±734 
CV% 24.6 55.6 59 44.6 124 110 94.8 72 86.7 67 
V1_F= initial dilution volume of distribution; K01=absorption rate constant; K10=elimination rate constant; 
K12=fractional rate constant from central compartment to peripheral compartment; K21=fractional rate constant from 
peripheral compartment to central compartment; CL_F=apparent oral clearance; V2_F=apparent volume of the 
peripheral compartment; Q_F=distribution clearance of peripheral compartment; AUC=area under the curve; 
Tlag=lag time in absorption 
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5.4.3 Pharmacodynamic modeling 
 
Fig 5.9 and 5.10 show the best cure fitting of the observed IMPDH enzyme activity –
time profiles of total and free MPA to the built-in IPR model (model 51, Inhibition of 
input model). 
 
After fitting all the data and by observing the fitting graph, IPR built in model (model 
51) (combined PK-PD model) fit well and can use model for the PK-PD relationship. 
Table 5.7 shows a summary of goodness of fit parameters for IPR built in model such 
as WSSR, AIC and R2. This model is continued to use for the patient group for 
population PK-PD modeling in the population PK-PD relationship analysis using 
WinNonMix (Non-Linear Mixed Effect). 
 
Table 5.7 Summary of goodness of fit parameters for total  and free MPA and IMPDH enzyme 
activity in Indirect Pharmacodynamic response built in model for individual patients for the 
conventional study following chronic oral dosing of MMF for more than 3 months 
 WSSR  DF  AIC      R2
Subjects 
IPR BIM  IPR BIM  IPR BIM  IPR BIM 
Total MPA        
LCLG 66  4  35.32407  0.9107 
TCKO 10.8195  4  22.66946  0.9899 
LWH 0.966  4  5.75943  0.9991 
Free MPA        
LCLG 77.574  4  32.10739  0.8839 
TCKO 8.02475  4  20.57771  0.9924 
LWH 31.59  4  30.16989  0.9705 














































Figure 5.9 Observed and predicted IMPDH enzyme activity-time course at steady state over the 
dosing interval (0 to τ) in patients for the conventional study following chronic oral dosing of 
MMF for more than 3 months based on total MPA, using indirect pharmacodynamic response 





























Figure 5.10 Observed- and predicted IMPDH enzyme activity-time course at steady state over 
the dosing interval (0 to τ) in patients for the conventional study following chronic oral dosing of 
MMF for more than 3 months based on free MPA, using indirect pharmacodynamic response 
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5.4.4 Pharmacodynamic parameter estimation 
 
Stable renal transplant patients for conventional study receiving chronic oral dosing of 
MMF for more than 3 months were used for model fitting of the PK-PD relationship 
with both total and free MPA concentrations. However, out of six patients, only three 
patients were included in this study as there was not enough data for the PD part 
(IMPDH enzyme activity) because of samples with insufficient MNC isolation or 
technical failure of MNC isolation.  
 
After fitting the data, this indirect pharmacodynamic response model fitted the data 
well. The estimated PD parameters related to total MPA and free MPA are presented 
in Table 5.8.   
 
Table 5.8 Estimated parameters for IMPDH enzyme activity of total and free MPA in 
stable RTx patients for the conventional study following chronic oral dosing of MMF for 
more than 3 months 
PD parameters [Estimate (CV %)] LCLG TCKO LWH Mean 
Total MPA .    
Kin (nmol/hr/mg protein)/hr 198.76 (79%) 998.47 (74%) 169.6 (46%) 455.61 
Kout (h-1) 3.38 (77%) 22.33 (63%) 1.05 (39%) 8.99 
IC50 (mg/L) 0.999 (47%) 4.39 (27%) 1.182 (24%) 2.19 
R2 0.9107 0.9899 0.9991  
df 4 4 4  
     
Free MPA     
Kin (nmol/hr/mg protein)/hr 626.67 (73%) 860.2 (83%) 241.11 (59.9) 575.99 
Kout (h-1) 22.6 (73.2%) 21.21 (84%) 5.67 (59%) 16.49 
IC50 (mg/L) 0.0735 (55%) 0.0321 (63%) 0.04 (18%) 0.0485 
R2 0.8839 0.9924 0.9705  
df 4 4 4  
Abbreviation: Kin=zero order rate for the production of response; Kout=first order rate constant for loss of response; 





In the present study, IC50 values for total MPA ranging from 0.999 – 4.39 mg/L 
(2.19±1.9 mg/L) (Table 5.9) are comparable with the literature reported values. 
Langman et al. [74] reported that MPA IC50 value for IMPDH activity in rabbit 
whole blood was similar to that (2-5 mg/L) for human whole blood and isolated 
lymphocytes in healthy volunteers. In. a study of Budde et al, MPA IC50 ranged 
between 1 and  5 mg/L (3.6±0.82 mg/L) using inhibitory Emax model (WinNonLin) 
in Caucasian RTxRs. Total MPA plasma concentration  above 5 mg/L are leading to 
>50% inhibition of IMPDH activity [63].  
 
The mean baseline IMPDH values (i.e., the ratio of Kin to Kout) in the individual 
model fitting for total MPA (50.67 nmol/h/mg protein) and free MPA (34.92 
nmol/h/mg protein) were found to be within the range 32.92 to 52.84 nmol/h/mg 
protein which was obtained from the renal transplant patients who were not on MMF. 
 
In our study, IC50 values for free MPA is 0.032 – 0.074 mg/L. To our knowledge, 

















MMF is an immunosuppressant that is widely used in combination with calcineurin 
inhibitors and corticosteroids for the prophylaxis of organ rejection in patients 
receiving allogeneic renal, cardiac or hepatic transplants. After its oral administration, 
MMF undergoes complex PKPD pathways. MMF, a prodrug, is rapidly absorbed 
from the gastrointestinal tract and extensively hydrolyzed to its active moiety MPA in 
the body. MPA is a potent, selective, uncompetitive and reversible inhibitor of 
IMPDH, which is an enzyme essential in de novo pathway of guanine nucleotide 
synthesis. Lymphocytes clonal expansion is dependent on de novo purine synthesis. 
MPA inhibits both B and T lymphocytes proliferation by inhibiting IMPDH. 
 
MMF is administered as a fixed dose in local hospitals and TDM is not done 
routinely, although dosage adjustments could be made in relation to clinical effects 
and measured trough concentrations at present. Currently, manufacturer guidelines for 
mycophenolate dosage are standard for all individuals within a transplant group. In 
adult renal transplant recipients, an oral dose of mycophenolate mofetil is prescribed 1 
g twice daily and this recommendation is largely based on the results from clinical 
trials carried out in the Western Caucasians population [100, 101]. Local trial 
conducted in SGH has also suggested the need for dosage reduction in the Asian 
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population to minimize risk of adverse effects. This suggests that covariates like age 




The main objective of this study was to develop a population pharmacokinetic 
pharmacodynamic model for mycophenolic acid in stable adult renal transplant 
patients in Singapore. The current recommended dosage for MMF is based on the 
studies done in the western population. Since the Asian population’s body weight and 
other biochemical markers differ from those of the west, it is worthwhile to conduct a 
study in Singapore of quantifying population mean values of pharmacokinetic and 
pharmacodynamic parameters of MPA, assessing inter- and intra-individual 
variability in PK & PD, and evaluating the influence of covariates such as existing 
disease, gender, and concomitant drug therapy on the PK-PD variability in Asian 
population. 
 
6.3 Patients and methods 
 
There were forty-nine stable RTxRs patients, including those (n=3, 
MMF/SRL/Steroids) with six intensive blood sampling time-points and those (n=46, 
MMF/CsA/Steroids or MMF/TAC/Steroids or MMF/SRL/Steroids) with single blood 
sampling time-point, for pharmacokinetic and pharmacodynamic analysis in this study 
(Table 6.1). All the inclusion and exclusion criteria were discussed in chapter 3. The 
written informed consent to participate in the study was obtained from all the patients 
recruited. Among the patients participated, three had a time series of 6 blood 
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samplings, while the others had a single blood sampling either at  0, 2 or 6 h (with its 
majority at 2 h) after oral administration of MMF. Plasma level of total and free MPA 
concentration and IMPDH enzyme activity were assayed using validated high-
performance liquid chromatography methods as described in sections 3.1, 3.2 and 3.4 
respectively. Relevant patients’ information such as demographics and covariates data 
prospectively collected was summarized in Table 6.1.  
 
The two-compartment disposition model with first order absorption (with lag time) 
and elimination was used for the pharmacokinetic modeling (see section 5.2.1.2, 
Equation 5.3) for both total and free MPA concentrations, while the simple Emax 
model was used for the phramacodynamic modeling. For a combined PK-PD model, 
physiological-based indirect model with inhibition of production process (Kin) was 
used as a link model between PK and PD (see section 5.3.1.1, Equation 5.11 and 
5.12).  
 
6.4 Data analysis 
 
All data for population PK (both total and free MPA concentrations) and population 
PK-PD analysis were analyzed using the nonlinear mixed effects modeling software 
program (WinNonMix Version 2.0.1, Pharsight ® Corporation, Cary, NC, USA).  
 
The same data set of patients was used for both development of population PKPD 
models and validation using leave-one-out cross validation method for the assessment 
of the predictive performance of the derived models. MMF doses of all the patients 
were converted to the MPA equivalent content by multiplying the MMF dose by 
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0.739 according to the following equation. (Ratio of the molecular weight of MPA to 







MPA ==   (Equation 6.1) 
Table 6.1 Demographics, comorbidities, concomitant immunosuppressants and biochemical 
parameters of stable renal transplant recipients who were on MMF for more than 3 months 
Different dosing regimen Patients’ Characteristics 
MMF/CsA/Steroid MMF/TAC/Steroid MMF/SRL/Steroid 
n 35 6 8 
Gender (M/F) 22/13 3/3 6/2 
Ethnic Group 26C / 6M / 2I / 1O 5C / 1M 5C / 2M / 1I 
Age 46.69±6.73(33-58) 43.67±9.44(31-56) 46.88±4.16 (38-49) 
Weight 68.41±15.09 (34-102) 62.68±16.28 (42.9-78) 
62.65±9.33 
(49.1-74) 
Comorbidities 32HTN / 14HL / 4DM 6HTN / 3HL / 2DM 6HTN / 2HL 
Creatinine clearancea (L/hr) 2.97±1.45 (0.64-6.39) 2.2±1.01 (0.83-3.84) 2.51±1.33 (1.19-5.3) 





Serum albumin levelc (g/L) 37.77±5.6 (26-47) 41.33±4.23 (34-45) 38.25±2.19 (35-41) 
Total serum bilirubind (μmol/L) 14.94±10.34 (4-63) 13.17±8.61 (4-27) 8.5±3.7 (4-14) 
Serum alkaline phosphatasee 
(U/L) 75.91±37.46 (33-235) 68.5±22.58 (45-102) 65±23.49 (30-110) 
Serum alanine transaminasef 
(U/L) 20.37±14.73 (4-71) 14.17±5.04 (8-22) 32.5±47.48 (9-149) 
Serum aspertate 
transaminaseg (U/L) 18.86±9.2 (10-57) 16.67±4.32 (12-22) 25.5±22.88 (11-81) 
Hemoglobinh (g/dl) 12.29±2.34 (7.9-16.6) 11.93±2.04  (10.2-15.3) 11.69±1.65 (9.8-14.8) 
Red blood cell counti (x1012/L) 4.2±0.82 (2.9-5.95) 4.18±0.59  (3.64-5.07) 4.21±0.55 (3.45-4.98) 
White blood cell countj (x109/L) 9.14±2.74 (4.87-16.7) 9.21±2.53  (5.1-12.73) 8.55±1.47 (6.93-11.69) 











































Abbreviations: M=male; F=female; C=Chinese; I=Indian; M=Malay; O=other; HTN=Hypertension; 
HL=Hyperlipidemia; DM=Diabetes Mellitus; MMF=mycophenolate mofetil; CsA=cyclosporine; 
TAC=tacrolimus; SRL=sirolimus; MPA=mycophenolic acid; MPAG=mycophenolic acid glucuronide; 
IMPDH=inosine 5’-monophosphate dehydrogenase; e.o.d.=every other day; o.m.=every morning; 
b.d.=twice a day;  
a Normal values for creatinine clearance: 5.1-8.1 L/hr 
b Normal values for serum creatinine: 53-132.6 μmol/L 
c Normal values for serum albumin: 35-50 g/L 
d Normal values for total serum bilirubin: 1.7-20.5 μmol/L 
e Normal values for serum ALP: 30-120 U/L 
f Normal values for serum ALT: 5-35 U/L 
gNormal values for serum AST: 5-40 U/L 
h Normal values for hemoglobin: 13.5-17.5 g/dL for males and 12-16 g/dL for females 
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i Normal values for red blood cell count: 4.3-6.2x1012/L for males and 3.8-5.5x1012/L for females 
j Normal values for white blood cell count: 4.1-10.9x109/L 
k Normal values for platelet count: 140-450x109/L 
 
6.5 Population pharmacokinetic modeling 
 
6.5.1 Model building procedure 
 
The population PK models for both total and free plasma MPA concentrations and 
population PK-PD model were built in a similar manner. 
 
Step 1: Basic structural PK model and PD link model (Covariate-Free Model) 
 
In the first step, the basic structural PK model and PD link model without any 
covariates was derived and data fitting to the model was performed. PK model was 
the two compartment PK model with first-order absorption (and lag time in 
absorption) and elimination, which was parameterized in terms of oral clearance (CL), 
initial dilution volume of distribution (V1), absorption rate constant (K01), peripheral 
volume of distribution (V2) and intercompartmental clearance (Q/F). Clearance and 
volume terms were modeled as apparent oral values (i.e. CL/F, V1/F and Q/F), but for 
simplicity, the oral availability terms (F) was not shown in the notation [99].  
 
Sequential approach population PK-PD modeling was used to get PK-PD parameter 
estimates. Population PK-PD modeling where patients’ PK parameter values obtained 
previously from population PK modeling were fixed as constants to get estimates of 
population means parameters. An accurate representation of the underlying PKPD, the 
basic structural model was built prior to initiating the population PKPD analysis. 
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 For the population PK-PD (PD link model), an integrated physiological indirect link 
model with Emax PD model which is also know as indirect response model. The PD 
model was parameterized in terms of Kin (zero order constant for production of 
response), Kout (first order constant for loss of response) and IC50 (the drug 
concentration which produces 50% of maximum inhibition). The first order (ML) 
method was used to evaluate the relation of total drug concentration and the drug 
response. The first order (GLS) method was used for the evaluation of the relation 
between free drug concentration and the response. 
 
Inter-individual variability η 
 
Inter-individual variability in all the PK parameters and PD link model parameters 
were described using exponential error models (Equation 6.2 and 6.3) 
 
For instance, MPA CL for the ith individual (CLi) and MPA IC50 for the ith 
individual (IC50i) were estimated using following equations:  
 
CLi =θpop*exp (ηijCL) (Exponential model) (Equation 6.2) 
 
where θpop represents the population mean value for MPA clearance (CLi); 
and ηijCL represents the inter-patient independent random effect with mean zero and 




IC50i =θpop*exp (ηiIC50) (Exponential model) (Equation 6.3) 
where θpop represents the population value for MPA IC50 (IC50i); 
and ηiIC50 represents the inter-patient independent random effect with mean zero and 
variance σ2 were symmetrically distributed variables, which specifies the inter-
individual variation around θpop, as IC50 i differs between patients. 
 
Intra-individual Variability ε 
 
Additive error models were tested to model intra-individual variability (residual error) 
in the various PK and PD parameters during the modeling process (Equation 6.4 and 
6.5). 
 
For instance, the observed MPA plasma concentrations for the jth individual at time i, 
(Ci, (tij)) and the observed enzyme activities (response) value for the jth individual at 
time i, (Ri, (tij))  were estimated using following equations: 
 
Cobs, ij= Cpred, ij+ (εij) (Additive model) (Equation 6.4) 
 
Robs, ij= Rpred, ij+ (εij) (Additive model) (Equation 6.5) 
 
where Cobs, ij is the observed response and Cpred, ij is the corresponding model predicted 
response for the jth individual at time i; εij and, Robs, ij is the observed response and 
Rpred, ij is the corresponding model predicted response for the jth individual at time i; 
εij represents the independent residual error distributed normally with mean 0 and 
variance σε2. εij accounts for all other unaccounted sources of intra-individual 
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variation in the model parameters such as misspecification of the PK and PD model, 
assay error, sampling and dosing time errors, errors in the recording, patient 
compliance, and the influences of covariates which are either not included, or 
unknown. 
 
The basic structural PK model without any covariates was derived and fitted to the 
data set. The values of the population PK parameters (CL, Q, V1, V2, K01 and LT) 
and PD parameters (Kin, Kout and IC50) were estimated along with the 
corresponding inter-individual variability parameters. The overall intra-individual 
variability parameter was also estimated.  
 
Model selection was based on three criteria [99]. (i) Statistical significance, given by 
a drop in the minimum objective function between successive models based on the χ2 
asymptotic assumption with the number of degrees of freedom equal to the difference 
in the number of parameters between the full and reduced model pairs. The 
significance level was set as P-value <0.05 which corresponds to an approximate drop 
in the minimum objective function of 3.8 units per one parameter difference in 
successive models. (ii) Plausible results i.e. PK parameter and PD parameter estimates 
were required to be physiologically plausible. In addition, the intra- and inter- subject 
variance values expressed as a coefficient of variation were required to fall between 1 
and 500% (values outside this range are often indicative of over-parameterization 
rather than a true representation of the variability. (iii) Model stability was assessed 
by changing the initial estimates of the parameters. The test should not significantly 
affect the final parameter estimates if the model is stable [99].  
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Finally, the adequacy of the developed models was evaluated based on the minimum 
objective function value (OFV), precision of the parameter estimates and graphical 
analyses of the goodness-of-fit plots. The basic structural model was selected and the 
OFV was used as a reference to assess the influence of the inclusion and exclusion of 
various covariates in the subsequent models. 
 
Step 2: Screening for Covariates 
 
Following the selection of the basic structural model, the influence of covariates was 
investigated. The screening and selection of covariates was performed in 2 steps. 
First, individual PK parameters and PD (link model) parameters obtained from the 
basic structural model were plotted against the demographics, comorbidities, 
concomitant immunosuppressants and biochemical parameters to assess possible 
relationships.  
 
Covariates were screened, including demographic factors like gender (G), age (Age), 
weight (Wt), ethnic group (EG), comorbidities such as diabetes mellitus (DM), 
hypertension (HTN), hyperlipidemia (HL); concomitant immunosuppressants such as 
cyclosporine (CsA), tacrolimus (FK), sirolimus (SRL); creatinine clearance  (CrCL), 
biochemical markers such as serum albumin (Alb), total serum bilirubin (BL), serum 
alkaline phosphatase (ALP), serum alanine transaminase (ALT), serum aspertate 
transaminase (AST), hemoglobin (Hb), red blood cell count (RBC), white blood cell 
count (WBC) and platelet (Plt) and MPAG peak concentration (MPAG). 
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The creatinine clearance of each subject was calculated from their age and gender 
using the aMDRD (abbreviated Modification of Diet in Renal Disease) formula which 
reflect GFR and Creatinine clearance [102] and expressed in units of L/hr. Then, the 
effect of individual covariates on the PK parameters and PD parameters was 
statistically assessed using analysis of variance (ANOVA) function in WinNonMix. 
Statistical significance was set at p≤0.05 at the covariate screening step. 
 
Step 3: Univariate analysis (Forward addition) 
 
In the first step, each of the significant covariates was first introduced separately into 
the base model to confirm its relevance. A decrease in the objective function value of 
at least 3.841 units (corresponding to p ≤ 0.05) was first required to consider the 
covariate in the intermediate model. Classically, a covariate was not retained at this 
step in case of obvious over-parameterization of the model. 
 
Covariates were introduced into addictive model. Categorical/ nominal variables have 
discrete sets of values such as gender, ethnic group, concomitant hypertension, 
diabetes mellitus and hyperlipidemia and concomitant medication with cyclosporine, 
tacrolimus and sirolimus. For ethnic group, the subjects were categorized into 4 
different groups: Chinese, Malay, Indian and Others. 
 
As an example, categorical variables for PK parameter CL and PD link model 





               θ9.FK+θ10.SRL (PK model) 
 
IC50ij =θpop+θ1.G+θ2.EGM+θ3.EGI+θ4.EGO+θ5.HTN+θ6.DM+θ7.HL+θ8.CsA+ 
               θ9.FK+θ10.SRL (PD link model) 
 
where θ1 to θ10 are fixed effects parameters. θ1.G is the fractional change in CL and  
IC50 in males (in females G=0 and in male G=1), θ2.EGM+θ3.EGI+θ4.EGO is the 
fractional change in CL and IC50 in Chinese (in Malay EGM=1 and in other ethnic 
groups EGM=0; in Indian EGI=1 and in other ethnic groups EGI=0; in other races 
EGO=1 and in other ethnic groups EGO=0), θ5.HTN is the fractional change in CL 
and IC50 for concomitant hypertension (in hypertensive HTN=1 and in non-
hypertensive HTN=0), θ6.DM is the fractional change in CL and IC50 for 
concomitant diabetes mellitus (in diabetic DM=1 and in non-diabetic DM=0), θ7.HL 
is the fractional change in CL and IC50 for concomitant hyperlipidemia (in 
hyperlipidemic HL=1 and in non-hyperlipidemic HL=0), θ8.CsA is the fractional 
change in CL and IC50 for the concomitant cyclosporine medication (in concomitant 
cyclosporine medication CsA=1 and in non-concomitant cyclosporine medication 
CsA=0), θ9.FK is the fractional change in CL and IC50 for the concomitant 
tacrolimus medication  (in concomitant tacrolimus medication FK=1 and in non-
concomitant tacrolimus medication FK=0), θ10.SRL is the fractional change in CL and 
IC50 for the concomitant sirolimus medication (in concomitant sirolimus medication 
SRL=1 and in non-concomitant sirolimus medication SRL=0 ).  
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Continuous/ regressor variables employ values from a continuous set which include 
age, weight, creatinine clearance, serum albumin, total serum bilirubin, alkaline 
phosphatase, alanine transaminase, aspertate transaminase, hemoglobin level, red 
blood cell count, white blood cell count, platelet count and MPAG peak 
concentration. 
 
As an example, continuous variables for the PK parameter CL and PD link model 
parameter IC50 were modeled using the following approach: 
 
CLij=θpop+θ11.Age+θ12.Wt+θ13.CrCL+θ14.Alb+θ15.BL+θ16.ALP+θ17.ALT+ 
θ18.AST+θ19.Hb+θ20.RBC+θ21.WBC+θ22.Plt+θ23.MPAG (PK model) 
 
IC50ij=θpop+θ11.Age+θ12.Wt+θ13.CrCL+θ14.Alb+θ15.BL+θ16.ALP+θ17.ALT+ 
θ18.AST+θ19.Hb+θ20.RBC+θ21.WBC+θ22.Plt+θ23.MPAG (PD link model)  
where θ11to θ23 are fixed effects parameters. 
 
The models for the effect of the covariates on V1, K01, V2 and Q are analogous to 
those for CL in PK model and Kin and Kout are analogous to those for IC50 for PD 
model (link model). 
 
Whether the inclusion of a covariate significantly improved the fit was determined by 
2 criteria. Firstly, the likelihood ratio test. For two hierarchical models, likelihood 
ratio tests to compare models were performed by comparing differences in OFV 
values between models to chi-square (χ2) distributions, with the degree of freedom 
(df) is equal to the difference in the number of the estimated parameters between the 
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full and reduced model pairs. The model with the lower OFV has a better goodness-
of-fit. A p-value of 0.05 was considered to be statistically significant, which 
corresponds with a decrease in OFV of 3.841 with one degree of freedom. If the 
inclusion of a covariate caused the OFV to decrease by >3.841, the covariate will be 
considered to be significant. 
 
Step 4: Multivariate analysis (Backward elimination) 
 
In the second step, all such significant covariates selected during the first step were 
included simultaneously into the basic model to get an intermediate model. To 
confirm its relevance in the population PK model, each covariate was independently 
removed from the intermediate model and the resulting variation in the OFV 
(compared to intermediate model) was examined after the removal. Statistically 
significance for backward elimination was set at p<0.05. If the elimination of a 
covariate caused an increase in the OFV of at least 3.841 units (df =1), the covariate 
would be retained in the final model. The final model, in which how many covariates 
were included or not, was produced from the results of backward elimination.  
 
In the selection of the final model, apart from backward elimination, the improvement 
in fit from the addition of the covariate to the model was also assessed by the 
precision of the parameter estimates and graphical analyses of the goodness-of-fit 
plots. In addition, the reductions in unexplained inter- and intra-individual variability 
were evaluated as criteria for covariate inclusion. 
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Those covariates which improved the curve fit from the basic structural model were 
included in the final model. 
 
6.5.2 Model validation 
 
Cross-validation method was used to check the robustness of the final model and its 
ability to predict the PK-PD data. Leave-one-out cross-validation was performed for 
the model validation. In the cross validation method, one subject’s data was left out. 
The curve fitting procedure for the remaining subjects’ data was then repeated and the 
pharmacodynamic response of that subject was subsequently predicted based on the 
estimates of PD parameters obtained from the whole but leave-one-out data. 
 
Predicted PD response of MPA obtained from each of the adult stable RTxRs using 
the leave-one-out approach was then compared to the corresponding observation to 
determine the predictive performance. 
 
The predictive performance of the final model was assessed in terms of ,the mean 
prediction error (ME), as a measure of  bias and  the root mean square prediction error 
(RMSE), as a measure of precision, and the associated 95% confidence intervals 
[103].  
 
Moreover, the fold error, FEj, for the prediction made on the basis of a specific 




10FEj =   (Equation 6.6) 
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where Rpred,j is the predicted response value based on a particular patients, j; Robs is the 




6.6.1 Population pharmacokinetic model of total MPA in stable RTxRs receiving 
chronic oral dosing on MMF for more than 3 months 
 
6.6.1.1 Structural model 
 
A total of 61 total MPA concentration-time data obtained from 49 patients who had 
been on MMF for more than 3 months were analyzed using WinNonMix software. A 


















Figure 6.1 Characteristic concentration-time profile of total MPA after chronic oral 




The data fitted the two-compartment model adequately, with first order absorption 
and elimination. Inter-and intra-individual variability was found to be best described 
by exponential error model. The first order (GLS) method was used as the 
approximation method. The estimated values of population PK parameters of the 
structural PK basic model and final model are summarized in Table 6.3. The 
goodness-of-fit plots are depicted in Figure 6.2. In the plot of predicted versus 
observed total MPA concentration, the concentration time points were randomly 
distributed and closely to the line of unity throughout the concentration. Similarly, in 
the plot of WRES versus predicted total plasma MPA concentration, the points 
showed random distribution throughout the predicted concentration. (See Fig. 6.2) 
 
6.6.1.2 Covariate analysis 
 
After screening the covariates using ANOVA, we observed that there were no 
statistically significant covariates for CL (See table 6.2). Hence, the final model was 
developed without any covariates added in. The estimated values of population PK 
parameters of the final PK model are the same as those of the basic structural PK 









Table 6.2 Illustration of testing of significance of covariates using ANOVA for PK parameter 
CL for total MPA 
Covariate P value Significance (p<0.05) 
0.7746 aNS Diabetes mellitus 
Concomitant sirolimus 0.1472 NS 
Concomitant tacrolimus 0.9281 NS 
Concomitant cyclosporine 0.0673 NS 
Hyperlipidemia 0.8504 NS 
Hypertension 0.9674 NS 
Age 0.8740 NS 
Ethnic Group 0.1200 NS 
Hemoglobin 0.5123 NS 
Red blood cell count 0.3325 NS 
Platelets count 0.6291 NS 
White Blood cell count 0.7955 NS 
Albumin level 0.7408 NS 
Bilirubin level 0.6044 NS 
Alkaline phosphatase level 0.8358 NS 
Aspertate transaminase level 0.0867 NS 
Alanine transaminase level 0.0537 NS 
Gender 0.0858 NS 
Weight 0.4684 NS 
Creatinine clearance 0.7057 NS 
aNS-Not Statistically significant 
 
Table 6.3 Estimates of population PK parameters of total MPA for the basic 
structural and final model  
Parameters Structural and final model OFV=181.29 Units [Estimate (CV %)] 
Pharmacokinetic parameters  
V1 (L) 7.81 (132.4) 
K01(1/hr) 2.57 (130.45) 
K10(1/hr) 0.379 (133.2) 
K12(1/hr) 7.45 (126.58) 
K21(1/hr) 0.1 (54.98) 
LT (hr) 0.53 (38.88) 
CL (L/hr) 2.91 (22.51) 
V2 (L) 870.63 (113.24) 
Q (L/hr) 755.54 (63.65) 
  
Inter-individual variability  
η V1  1.06x10-18 (1.03x10-7) 
η K01  7.47 (273) 
η K10 0.133 (36.5) 
η K12 0.42 (65) 
η K21 4.7 (217) 
η LT  0.4 (63.2) 
η CL  0.00219 (4.7) 
η V2  0.3167 (56.2) 
η Q  0.0016 (0.04) 
  
Intra-individual variability  
 ε 0.00696 (2.26) 
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Table 6.4 Difference in AIC and SC values for PK models(total MPA) 
Models AIC SC 
Basic structural model 324.75 350.85 
Final model 324.75 350.85 
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Figure 6.2 Goodness-of-fit plot for the basic structural model : (A) Predicted total MPA 
concentration versus observed total MPA concentration (population) : (B) Predicted total MPA 
concentration versus observed total MPA concentration (individual) : (C) Weighted residuals 
(WRES) versus predicted total MPA concentration (population) : (D) Weighted residuals 


















Figure 6.3 Plot of predicted (population and individual) total MPA concentration against time 
 
 
6.6.2 Population pharmacokinetic model of free MPA in stable RTxRs receiving 
chronic oral dosing on MMF for more than 3 months 
 
6.6.2.1 Structural model 
 
A total of 61 free MPA concentration-time data obtained from 49 patients who had 
been on MMF for more than 3 months were analyzed using WinNonMix software. A 


















Figure 6.4 Characteristic concentration-time profile of free MPA after chronic oral 
administration of MMF for more than 3 months 
 
The free MPA data fitted a two-compartment model adequately, with first order 
absorption and elimination with exponential error model for both inter-individual and 
intra-individual variabilities. The first order (GLS) method was used as the 
approximation method. 
 
Table 6.6 summarizes all the estimated values of population PK parameters of free 
MPA for the structural basic and final model of the PK model. 
 
Goodness-of-fit plots are depicted in Figure 6.5. In the plot of predicted versus 
observed free MPA concentration, the concentration time points were randomly 
distributed and closely to the line of unity throughout the concentration. Similarly, in 
the plot of WRES versus predicted free MPA concentration, the points showed 






6.6.2.2 Covariate analysis 
 
After screening the covariates using ANOVA, we observed that there were no 
statistically significant covariates for CL (See table 6.5). Hence, the final model was 
developed without any covariates added in. The estimated values of population PK 
parameters of free MPA for the final model are the same as those of the basic 
structural PK model (Table 6.6). 
 
Table 6.5 Illustration of testing of significance of covariates using ANOVA for PK parameter 
CL for free MPA 
Covariate P value Significance (p<0.05) 
0.6235 aNS Diabetes mellitus 
Concomitant sirolimus 0.2699 NS 
Concomitant tacrolimus 0.2283 NS 
Concomitant cyclosporine 0.0585 NS 
Hyperlipidemia 0.4866 NS 
Hypertension 0.1250 NS 
Age 0.8941 NS 
Ethnic Group 0.4170 NS 
Hemoglobin 0.4241 NS 
Red blood cell count 0.2940 NS 
Platelets count 0.5555 NS 
White Blood cell count 0.0729 NS 
Albumin level 0.7473 NS 
Bilirubin level 0.7152 NS 
Alkaline phosphatase level 0.8312 NS 
Aspertate transaminase level 0.8804 NS 
Alanine transaminase level 0.0538 NS 
Gender 0.2300 NS 
Weight 0.1880 NS 
Creatinine clearance 0.06273 NS 







Table 6.6 Estimates of population PK parameters of free MPA for the basic structural 
and final model  
Parameters Structural basic and final model OFV=-
402.99 Units [Estimate (CV %)] 
Pharmacokinetic parameters  
V1,u (L) 158.56 (451.6) 
K01 (1/hr) 1.247 (162.5) 
K10 (1/hr) 1.946 (133.2) 
K12 (1/hr) 7.45 (452.1) 
K21 (1/hr) 91.657 (47.34) 
LT (hr) 0.1 (204.8) 
CLu (L/hr) 876.28 (565.80) 
V2,u (L) 135760 (14.93) 
Qu (L/hr) 14392 (9.57) 
  
Inter-individual variability  
η V1,u  9.61x10-12 (3.1x10-4) 
η K01  1.59 (126) 
η K10 1.37 (117) 
η K12 9.35x10-9 (9.67x10-3) 
η K21 3.36x10-36 (1.83x10-16) 
η LT  7.74x10-26 (230.88) 
η CLu  5.33 (6.17x10-3) 
η V2,u  0.598 (77.3) 
η Qu  0.0189 (13.7) 
  
Intra-individual variability  
 ε 6.8x10-5 (3.8) 
 
Table 6.7 Difference in AIC and SC values for PK models (free MPA) 
Models AIC SC 
Basic structural model -226.88 -241.55 
Final model -226.88 -241.55 
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Figure 6.5 Goodness-of-fit plot for the basic structural model: (A) Predicted free MPA 
concentration versus observed free MPA concentration (population): (B) Predicted free MPA 
concentration versus observed free MPA concentration (individual): (C) Weighted residuals 
(WRES) versus predicted free MPA concentration (population): (D) Weighted residuals (WRES) 




















6.6.3 Population PK-PD model of total MPA in stable RTxRs receiving chronic 
oral dosing of MMF for more than 3 moths 
 
6.6.3.1 Structural model 
 
Forty nine patients with 61 data points were analyzed using WinNonMix software. A 
typical IMPDH enzyme activity of MPA after oral administration of MMF shows a 
rapid decline, which is inversely related to the rapid rise of MPA concentration, and a 
gradual restoration of enzyme activity as the MPA level decreased with time after 
reaching its peak concentration (Figure 6.7). 
 
The population mean values of Kin, Kout and IC50 together with inter-and intra-
patient variabilities have been quantified in the present study for 49 patients. Table 
6.10 summarizes all the estimated values of population PD parameters of MPA for the 
basic structural and final PK-PD model. 
 
Figure 6.8 showed the goodness-of-fit plots when predicted versus observed PD 
response was drawn, it was seen that the response points were distributed randomly 
and close to the line of unity. Likewise, when fitting with the points of WRES versus 
predicted PD response, random distribution was observed throughout. 
 
6.6.3.2 Covariate analysis 
 
The ANOVA function showed the following significant factors (p<0.05): G, Wt and 
CrCL with IC50 (See table 6.8). There was no statistically significant drop in OFV 
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when incorporated each of the significant covariates into the basic model. Hence, the 
final model was developed without any covariates added in. Table 6.9 shows the 
model development and change in OFV values. The estimated values of population 
PK-PD parameters of the basic and final PK-PD model are thus the same as those of 
the basic structural PK-PD model (Table 6.10). 
 
Table 6.8 Illustration of testing of significance of covariates using ANOVA for PD parameter 
IC50 
Covariate P value Significance (p<0.05) 
0.5320 aNS Diabetes mellitus 
Concomitant sirolimus 0.3892 NS 
Concomitant tacrolimus 0.3644 NS 
Concomitant cyclosporine 0.3545 NS 
Hyperlipidemia 0.0819 NS 
Hypertension 0.1332 NS 
Age 0.1574 NS 
Ethnic Group 0.3356 NS 
Hemoglobin 0.1199 NS 
Red blood cell count 0.2533 NS 
Platelets count 0.5169 NS 
White Blood cell count 0.5629 NS 
Albumin level 0.7756 NS 
Bilirubin level 0.9576 NS 
Alkaline phosphatase level 0.9610 NS 
Aspertate transaminase level 0.3417 NS 
Alanine transaminase level 0.0682 NS 
0.0424 bS Gender 
Weight 0.03264 S 
Creatinine clearance 0.02258 S 
aNS-Not Statistically significant, bS-Statistically significant 
 
Table 6.9 Model Development   
Models Minimum OFV X2 (P<0.05) Change in OFV Significance 
Screening individual covariates for significance 
Basic model 342.52 NA NA NA 
f(G) 350.21 Increase in OFV NA NS 
f(Wt) 342.28 0.24 NA NS 
f(CrCL) 358.88 Increase in OFV NA NS 





























Figure 6.7 Time course of IMPDH enzyme activity PD profile of MPA after chronic oral dosing 




Table 6.10 Estimates of population PD parameters of total MPA for the basic 
structural and final PK-PD model  
Parameters Structural basic and final model OFV=342.52 Units [Estimate (CV %)] 
Pharmacodynamic parameters  
Kin (nmol/h/mg protein/h) 344.51 (98.7) 
Kout (1/h) 6.99 (98.5) 
IC50 (mg/L) 5 (20.7) 
  
Inter-individual variability  
η Kin  0.117 (34.2) 
η Kout  2.08x10-30 (1.44x10-13) 
η IC50  2.41x10-5 (0.664) 
  
Intra-individual variability  
 ε 42.11 (25.26) 
 
Table 6.11 Difference in AIC and SC values for PKPD models (response of total MPA) 
Models AIC SC 
Basic structural model 468.48 481.24 
Final model 468.48 481.24 
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Figure 6.8 Goodness-of-fit plot for the basic structural model : (A) Predicted response of total 
MPA versus observed response of total MPA (population) : (B) Predicted response of total MPA 
versus observed response of total MPA (individual) : (C) Weighted residuals (WRES) versus 
predicted response of total MPA (population) : (D) Weighted residuals (WRES) versus predicted 
response of total MPA (individual)  
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The results of the predictive performance evaluation for the final PK-PD model, using 
the leave-one-out cross-validation are presented in Table 6.12. Prediction was 
unbiased and fairly precise (CV% 27.61%) as their respective 95% confidence 
intervals included zero. A scatter plot of observed vs final model-predicted PD 
response with r2=0.8913 (p<0.05) is shown in Figure 6.9.  
 
Table 6.12 Predictive performance of population PKPD model using total MPA 
concentration and response in stable RTxRs (n=49) 
Population  Covariate Model   
Bias (nmol/h/mg protein)  0.21 
95% confidence interval  (-13.63-14.04) 
   
Precision (nmol/h/mg protein)  7.002664 (27.61%) 
95% confidence interval  (-2.36838-16.37371) 
   
 
 





























6.6.4 Population PK-PD model of free MPA in stable RTxRs receiving chronic 
oral dosing of MMF for more than 3 moths 
 
6.6.4.1 Structural model 
 
The population PK-PD model for free plasma MPA was built in a similar manner as 
the total plasma MPA. 
 
49 patients with 61 data points were analyzed using WinNonMix software. The 
population mean values of Kin, Kout and IC50 together with inter-and intra-
individual variabilities have been quantified for the free MPA. Table 6.15 summarizes 
all the estimated values of population PD parameters of free MPA for the basic 
structural PK-PD model. 
 
Figure 6.10 displayed the goodness-of-fit parameters. When observed PD response 
was drawn against predicted value, symmetrical and random pattern were plotted 
along the line of unity. A similar pattern was also seen in WRES versus predicted 
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Figure 6.10 Goodness-of-fit plot for the basic structural model : (A) Predicted response of free 
MPA versus observed response of free MPA (population) : (B) Predicted response of free MPA 
versus observed response of free MPA (individual) : (C) Weighted residuals (WRES) versus 
predicted response of free MPA (population) : (D) Weighted residuals (WRES) versus predicted 
response of free MPA (individual)  
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6.6.4.2 Covariate analysis 
 
The analysis of the relationship between patient covariates and pharmacodynamic 
parameters produced an intermediate model. The ANOVA function showed the 
following correlations: ethnic groups, diabetes mellitus and white blood cell count for 
IC50 at p<0.05 and the results of covariate analysis from ANOVA are shown in Table 
6.13. 
 
Each of the significant covariates as determined from ANOVA was introduced 
individually into the basic structural model. The covariates that individually caused a 
statistically significant drop in OFV when incorporated into the basic model were 
white blood cell count and diabetes mellitus for PD model IC50. All the OFV values 
obtained are summarized in Table 6.14. 
 
After screening the individual covariates for significance, only white blood cell count 
(WBC) showed significant. So, backward elimination was not necessary to perform. 
WBC count an important covariate was incorporated in the final model.  
 
This inclusion of the covariate in the final model explained both inter- and intra-
individual variability for IC50 when compared to the basic structural PKPD model. 
The estimated inter-individual variability for IC50 was decreased from 0.0006 to 




The estimated values of population PD parameters of free MPA for the final model 
are presented in Table 6.15 and the goodness-of-fit plots for the final model is 
illustrated in Figure 6.11. An example of the plot of predicted (population and 
individual) PD response of free MPA versus free MPA concentration generated from 
the final model for individual subject is shown in Figure 6.12. 
 
Table 6.13 Illustration of testing of significance of covariates using ANOVA for PD parameter 
IC50 
Covariate P value Significance (p<0.05) 
0.1625 aNS Gender 
Concomitant sirolimus 0.3109 NS 
Concomitant tacrolimus 0.9081 NS 
Concomitant cyclosporine 0.7853 NS 
Hyperlipidemia 0.5651 NS 
Hypertension 0.2588 NS 
Age 0.2698 NS 
Weight 0.2387 NS 
Hemoglobin 0.6454 NS 
Red blood cell count 0.0692 NS 
Platelets count 0.6136 NS 
Creatinine clearance 0.4039 NS 
Albumin level 0.5359 NS 
Bilirubin level 0.5151 NS 
Alkaline phosphatase level 0.9663 NS 
Aspertate transaminase level 0.524 NS 
Alanine transaminase level 0.9676 NS 
0.0062 bS Diabetes mellitus 
Ethnic groups 0.0154 S 
White blood cell count 0.0185 S 
aNS-Not Statistically significant, bS-Statistically significant 
 
Table 6.14 Model Development   
Models Minimum OFV X2 (P<0.05) Change in OFV Significance 
Screening individual covariates for significance 
Basic model 352.76 NA NA NA 
f(DM) 373.07 Increase in OFV NA NS 
f(EG) 352.9 Increase in OFV NA NS 
f(WBC) 341.19 11.57 3.841 S 




Table 6.15 Estimates of population PD parameters of free MPA for the basic structural 
and final PK-PD model 
Structural model 
OFV=352.76 Units 
[Estimate (CV %)] 
Final model OFV=341.19 
Units [Estimate (CV %)] Parameters 
Pharmacodynamic parameters   
Kin (nmol/h/mg protein/h) 553.42 (154.39) 498.09 (15.61) 
Kout (1/h) 13.41 (168.13) 12.84 (15.83) 
IC50 (mg/L) 0.0299 (33) 0.0343 (6.42) 
   
Inter-individual variability   
7.35x10-18(2.69x10-7) 4.01x10-30 (2x10-13) η Kin  
7.62x10-2 (27.60) 4x10-30 (2x10-13) η Kout  
4.81x10-1 (69.32) 4.31x10-1 (65.65) η IC50  
   
Intra-individual variability   
 ε 15.18 (15.7) 8.124 (10.99) 
   
Covariates for IC 50   
WBC NA 0.0001 (212.41) 
 
Table 6.16 Difference in AIC and SC values for PKPD models (response of free MPA) 
Models AIC SC 
Basic structural model 471.1 483.86 
Final model 479.15 494.04 
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Figure 6.11 Goodness-of-fit plot for the final model : (A) Predicted response of free MPA versus 
observed response of free MPA (population) : (B) Predicted response of free MPA versus 
observed response of free MPA (individual) : (C) Weighted residuals (WRES) versus predicted 
response of free MPA (population) : (D) Weighted residuals (WRES) versus predicted response 




















Figure 6.12 Plot of predicted (Population and Individual) PD response of free MPA versus free 
MPA concentration (final model) 
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6.6.4.3 Model validation 
 
The PD response of free MPA was predicted based on the final PK-PD model, using 
leave one out method, was compared to that observed to determine the predictive 
performance. The prediction was found to be unbiased, with ME (95% CI) of -0.07 
nmol/h/mg protein (-6.82-6.69 nmol/h/mg protein) and also satisfactorily precise 
(95% CI) of 3.419865 nmol/h/mg protein (13.33%) (-0.74693-7.586656 nmol/h/mg 
protein) (Table 6.17). A scatter plot of observed versus final model-predicted 
response is shown in Figure 6.14 (r2=0.9262, p value<0.05). 
 
Prediction of pharmacodynamic response of free MPA in the in vivo from the adult 
stable renal transplant patients were made by simulation using leave one out method 
and those predicted data were compared with the real observations to determine the 
predictive performance. 
 
Table 6.17 Predictive performance of population PKPD model using free MPA 
concentration and response in stable RTxR (n=49) 
Population  Covariate Model   
Bias (nmol/h/mg protein)  -0.07 
95% confidence interval  (-6.82-6.69) 
   
Precision (nmol/h/mg protein)  3.419865 (13.33%) 
95% confidence interval  (-0.74693-7.586656) 
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There are very few population PK-PD studies of MMF especially in Asian renal 
transplant patients. Our study reported the PK-PD modeling of MPA for both free and 
total MPA in stable renal transplant patients from the local hospital. The total or free 
MPA concentration-time profiles were fitted to a two-compartment model with first 
order absorption (including lag time in absorption) and elimination, using population 
PK modeling approach. The values of PK parameters obtained were then fixed when 
population PK-PD modeling was performed to estimate the population PD 
parameters, using the indirect physiologic link model to bridge between the 
pharmacodynamic Emax response model and the PK model. 
 
There have been no reported values of PD parameters such as Kin and Kout for MPA 
in RTx patients. In this study, the estimated values of PD parameters, Kin, Kout and 
IC50, of total MPA in the final PK-PD model were 344.51nmol/h/mg protein/h, 7.1/h 
and 5 mg/L respectively. Our finding for the estimated value of IC50 (5 mg/L) was 
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close to the reported value of IC50 (3.6±0.82 mg/L), using Inhibitory effect Emax 
model approach in Caucasian renal transplant patients [63] and was in agreement with 
the finding of Filler G et al. showing that a 50% inhibition of IMPDH, proposed to be 
sufficient for immunosuppression, was achieved when MPA Cmin was between 2-5 
mg/L in adults [105]. Within the therapeutic range of MPA IC50 2-5 mg/L, the 
adequate percent inhibition of IMPDH in renal transplant patients ranged from 23 to 
60% [106].  
 
Significant covariates for IC50 (based on total MPA concentration) were gender, 
weight and creatinine clearance, using build-in ANOVA in WinNonMix for 
preliminary screening. Further univariate and multivariate analyses were subsequently 
done, indicating that none of these chosen covariates reached statistical significance. 
It is likely due to the fact that just free drugs (unbound), not the total MPA, acts on the 
receptors and free MPA only has been shown to be the pharmacologically active 
portion of MMF. Average bound fraction of MPA to plasma albumin is as extensive 
as 97.5% in individuals with normal renal function. Therefore, the clinical effect of 
MMF is probably related to the capacity of plasma to maintain a release of MPA to 
active lymphocytes [107]. It is, however, recommended that those covariates should 
be considered as potential covariates when designing future study. Population PK-PD 
studies with a larger sample size with full covariates information are needed to gain a 
clearer picture of the influence of covariates on PKPD profile of MPA.  
 
In this study, the estimated values of PD parameters, Kin, Kout and IC50, of free 
MPA in the final PK-PD model were 498.09 nmol/h/mg protein/h, 12.84/h and 
0.0343mg/L respectively. It is observed that the findings are consistent with the 
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individual model fitting. The mean baseline IMPDH values (i.e., the ratio of Kin to 
Kout) in the final model for total MPA (48.52 nmol/h/mg protein) and free MPA 
(38.79 nmol/h/mg protein) were found to be in line with the values obtained from the 
renal transplant patients who were not on MMF, ranging from 32.92 to 52.84 
nmol/h/mg protein. 
 
Significant covariates for IC50 (based on free MPA concentration) were diabetes 
mellitus, ethnic groups and white blood cell count, using build-in ANOVA in 
WinNonMix for preliminary screening. Further univariate analysis showed that 
among all the three covariates tested, the only one retained was white blood cell 
count. Thus, WBC count could be an important covariate affecting the PD response of 
free MPA. 
 
Previous studies provide some evidence of the relationship among free concentration 
of MPA, IMPDH activity and WCB count. The finding of Langman et al .showed a 
sigmoidal relationship between WBC count and IMPDH activity [74]. It has been 
found that both inhibition of IMPDH and suppression of proliferation in mitogen-
stimulated lymphocytes depend on free MPA concentration in vitro [65]. According 
to the tight-binding inhibitor kinetics, IC50 values for tight-binding inhibitors 
increase, whereas those for weak-binding inhibitors do not change, as the target 
enzyme concentration is increased [108]. Korecka et al. reported that the IC50 values 
of MPA increased with the IMPDH enzyme concentration, suggesting that MPA is 
the tight binding inhibitor of IMPDH activity [87]. 
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Moreover, Langman et al. [74] reported that the iner-individual variation in IMPDH 
activity in whole blood (either human or rabbit) was not reduced by correcting the 
results for WBC content. However, that analysis was performed in healthy subjects, 
who exhibited minimal inter-individual variation of WBC count; this is in contrast to 
transplant recipients. 
 
To our knowledge, there have been no published reports on the relationship between 
PK & PD and the influence of covariates on MMF. More work with a larger sample 
size has to be done to confirm the importance of WBC count as the sample size was 






















Mycophenolic acid is known to preferentially inhibit the type II isoform of IMPDH in 
a noncompetitive and reversible manner. With time, this blockade of IMPDH II may 
either induce the over-expression of the IMPDH II gene (because cellular alterations 
in guanosine triphosphate pools have been shown to be associated with inverse 
changes in the gene expression of IMPDH II) or activate an alternative way of 
guanosine production through the induction of the type I isoform of IMPDH.  
 
Several approaches can be used to assess the appropriateness of the dosing regimen 
for immunosuppressive drugs. The first involves assessment of clinical response. This 
approach has its limitations, since signs of rejection to toxicity may be difficult to 
recognize clinically. The second involves assessment of the PK properties of drug and 
relating various PK parameters (i.e., trough levels, area under the curve etc.) to 
immunosuppressive efficacy or toxicity. This approach also has its limitations, since 
the apparent concentrations of the drug measured may not reflect the 
pharmacologically active concentration, owing to cross reactivity of inactive 
metabolites in the assays. In addition, therapeutic range for drug has been difficult to 
establish because of dependency on the type of transplant, the time post transplant and 
the regimen of the immunosuppressive drugs used in the combination with the drug of 
interest. The third, a PD approach, involves the measurement of the biological effect 
of the drug to monitor therapy and allows for dosage adjustments to optimize 
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immunosuppression and minimize side effects [91]. This alternative PD approach 
involves the measurement of the degree of inhibition of the enzyme IMPDH in 
peripheral blood lymphocytes, and its correlation with MPA plasma concentration 
which has the potential to augment pharmacokinetics and trough concentration 
monitoring to optimize the dosing regimen of immunosuppressive drugs [48].  
 
In the present study, the established reversed-phase HPLC methods [5, 59] with UV 
detection were applied to quantify MPA and MPAG in patients’ plasma, urine and 
ultrafiltrates. Determination of the IMPDH activity was performed using the 
established methods of Glander et al. (2001) and Brouwer et al. (2006) with some 
minor modification. It was applied successfully to quantify immunosuppression by 
MMF administered patients. Within the therapeutic range of MPA IC50 2-5 mg/L, the 
adequate percent inhibition of IMPDH in renal transplant patients ranged from 23 to 
60% [106]. Similarly, in our study, mean MPA IC50 2.19±1.9 mg/L produced 13.05 
to 62.24% inhibition of IMPDH activity. The requirement of small amount (3 ml 
instead of 5 ml literature value) of blood volume and small number (1x106 cell/ml 
lysate) of cell counts could be potentially useful for determination of IMPDH activity 
in a PD study. Although the measurement of IMPDH activity may provide more 
direct information on the functional activity of MMF therapy in vivo and may increase 
the efficacy and safety of MMF therapy, the proposed IMPDH assay can compliment 
the currently accepted routine therapeutic drug monitoring (TDM) of MPA which is 
substantiated with concentration outcome studies [109].  
 
There was a wide inter-individual variation of IMPDH activity ranging from 5.15 to 
55.03 (25.43±12.03, n=46) nmol/h/mg protein (Table 3.4). There was a significant 
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negative correlation between logarithmic MPA plasma concentration, either total or 
free, and IMPDH activity in lymphocytes. Moreover, there was a weaker correlation 
between logarithmic MPAG plasma concentration, either total or free, and IMPDH 
activity in lymphocytes. These findings suggest that either MPA or IMPDH 
monitoring could play a certain role in the improvement of individual 
immunosuppressive therapy. Further investigations with a large number of patients 
are needed to fully explore the impact of covariates on the PK-PD relationship 
between MPA and IMPDH activity.  
 
Six adult stable RTxRs who were on MMF/SRL/Steroids for more than 3 months 
were selected to investigate the basic PK profile of MPA and its major metabolites 
MPAG and the corresponding PD profile of MPA (i.e., IMPDH activity) within the 
dose intervals (Table 4.1).  
 
The 12-h PK profile of both total and free MPA concentrations from all patients 
showed same patterns (Figure 4.1). There was a rapid increase in total and free MPA 
concentration during the absorption phase, followed by a rapid distribution and slow 
elimination phase. The MPA AUCss and C0 values presently observed after low dose 
of MMF with SRL combination are quite close to those previously reported after 
higher dose of MMF with TAC or CsA combination (Table 4.3). This study confirms 
that patients taking MMF and SRL experience a higher exposure to active MPA but 
with lower exposure to inactive MPAG. 
 
In the protein binding study, the free fraction of MPA was 0.4 to 1.06 %, while that of 
MPAG was 11.17 to 27.89%, that means approximately 99% MPA and 73 to 89 % of 
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MPAG bound to serum albumin suggesting that a lesser chance of MPAG 
displacement effect on MPA takes place in patients, dosed with MMF and SRL 
combination, experiencing lower MPAG exposure. 
 
In our chronic and stable patients studied (Figure 4.1), IMPDH activity at C0 (i.e., 
MPA concentration before next dose) and Cτ (i.e., MPA trough concentration after 
dose) was quite close to each other and appears to be inversely related to total or 
unbound MPA plasma concentration, suggesting that the change in IMPDH activity is 
reversible, which is a function of MPA concentration  
 
Two pharmacokinetic models, one compartment and two open compartment model 
with first-order absorption and elimination, were used to fit the time profile of total 
and free MPA concentration in the six patients studied. Based on the goodness-of-fit 
parameters, these two models were discriminated, the former being statistically 
inferior compared to the latter. For the combined PK-PD model, a physiological 
indirect response model was used as a link between the Emax (PD) model and the two 
compartment (PK) model. The PK-PD combined model developed was employed as a 
basic model for the subsequent population PK-PD data analysis.  
 
Exponential and linear error models were found adequately to describe inter- and 
intra-individual variability, respectively, in the population modeling. With a 
population PK-PD model, patient covariates were screened for their impact on the 
model parameters, to account for the variability of MPA in pharmacokinetics and 
pharmacodynamics. MPAG was not included in the modeling as the reported value of 
IC50 for MPAG, the glucuronide metabolite of MPA, was >100 mg/L,  indicating that 
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its inhibitory effect on IMPDH activity was <5% of that for MPA [74]. Patient 
covariates had no significant impacts on the PK parameters, such as oral clearance, of 
total and free MPA, nor on the PD parameters, such as IC50, of total MPA. White 
blood cell count appeared to be the sole important covariate affecting the IC50 of free 
MPA, substantially reducing inter-individual variation in this PD parameter by 5.3% 
and intra-individual variation by 25.47% (Table 6.15). Finally, a combined population 
PK-PD model was developed and validated, which may allow for accurate prediction 
of individual’s patient response (or dosage regimen) based on the population PK and 
PD parameters of free MPA and individual’s MPA dosage regimen (or desired 
response) and white blood cell count.  
 
7.2 Future Perspectives 
 
The monitoring of blood concentration of immunosuppressants is a well-established 
practice for calcineurin inhibitors (cyclosporine) and for MMF. This helps to ensure 
minimal effective concentration (Cmin) and, more particularly, to avoid toxicity, but 
this monitoring provides only a poor idea of the degree of immunosuppression 
attained in an individual patient. The efficacy of an immunosuppressant probably 
depends on the interaction between the active form and the target IMPDH enzyme 
during the entire dosing interval. This interaction depends on a combination of factors 
such as the absorption pattern, plasma transport proteins, cyto-plasma binding 
proteins, the timing of the metabolism of the immunosuppressant, and the activity, if 
present, of metabolites. For these reasons, several methods have been proposed to 
measure more directly the efficacy of immunosuppressants in individual patients. 
 176
Some of these methods are based on the measurement of the activity of the putative 
immunosuppressant’s target enzyme [110].  
 
Several studies including the present study show a large inter-patient variability in 
both the basal .IMPDH level (i.e., IMPDH activity prior to its next MMF dose) and 
the time required for a recovery of enzyme activity to the basal level However, the 
proposed IMPDH assay could not replace the widely accepted routine PK monitoring 
of MPA, which was substantiated with concentration outcome studies [109]. Hence, 
further experimentations like a real-time polymerase chain reaction (PCR) quantifying 
the IMPDH II gene expression in transplant patients could be carried out to examine 
the genetic factors influencing MMF efficacy and tolerability, which is known as 
pharmacogenetics of IMPDH II in peripheral mononuclear cells. Perhaps, 
pharmacogenetic monitoring could play an important role in the improvement of 
individual immunosuppressive therapy.  
 
The clinical utility of the measurement of IMPDH activity in lymphocytes should be 
further assessed in future studies involving more specific transplant patients groups 
under MMF therapy. More work has to be done using larger sample size and more 
sampling time points in order to obtain clearer picture about the impact of patient 
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